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Abstract  There is little consensus about measurement of physical activity in adults with muscular dystrophy. This 
systematic review summarizes evidence for measurement properties of direct and indirect measures of physical 
activity in adults with muscular dystrophy. A two-phase search for peer-reviewed articles identified firstly, studies 
which measured physical activity in this population and secondly, studies reporting the measurement properties of 
activity measures. Methodological quality was assessed using COSMIN guidelines and a best evidence synthesis 
conducted. Phase 1 included 53 studies identifying 63 measures including accelerometers, direct observation, 
heartrate monitors, calorimetry, positional sensors, activity diaries, single scales and questionnaires. Phase 2 
included 26 studies of measurement properties for 32 measures. Methodological quality of the included studies was 
low, only 2 were rated good. There was insufficient evidence to robustly recommend any physical activity measures 
and further research is required to validate measures of physical activity for adults with muscular dystrophy. Based 
on the findings of this review, measures with potential for further study have been highlighted. 
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Cite This Article: Sarah F. Roberts-Lewis, Michael R. Rose, Claire M. White, and Farah Seedat, 
“Measurement of Physical Activity in Adults with Muscular Dystrophy: A Systematic Review.” Journal of 
Physical Activity Research, vol. 4, no. 1 (2019): 1-25. doi: 10.12691/jpar-4-1-1. 
1. Introduction
The aim of this review was to appraise measures of physical 
activity for the assessment of adults with muscular dystrophy. 
Effective physical activity measurement is important to 
evaluate outcomes in randomised controlled trials (RCTs), 
to monitor disease progression and to make recommendations 
for optimising physical activity [1]. For adults with muscular 
dystrophy, physical activity has been linked to health 
benefits, such as improved fitness and self-management [2,3]. 
However, more research reporting quantified physical activity 
levels is required to determine optimal activity for adults 
with muscular dystrophy and to evaluate potential risks, 
such as exercise-induced damage to dystrophic muscle [4,5].  
Figure 1. FITT framework for measurement of physical activity. 
Diagram created by author (SRL) based on common clinical practice and 
physical activity measurement analysis frameworks applied in the 
literature [8,9] 
Physical activity is defined as behaviours involving 
bodily movements and energy expenditure [6,7]. Measurement 
of physical activity can be defined using a well-recognised 
conceptual framework [8,9] which considers Frequency, 
Intensity, Timing and Type (FITT) of activity or overall 
measurement encompassing these parameters (see Figure 1).  
The qualities of measurement tools can be defined 
in terms of measurement characteristics and properties, 
according to the COnsensus-based Standards for the 
selection of health Measurement INstruments (COSMIN) 
taxonomy [10] (see Figure 2). 
Measurement characteristics (generalizability and 
interpretability) of physical activity measures are variable 
because they depend on population and setting, and because 
there are numerous diverse ways to measure physical 
activity. These include indirect self-report tools, such as 
diaries and questionnaires, and direct tools which record 
the physiological consequences of activity, including bodily 
movements, metabolism and cardio-respiratory responses 
[11,12]. The characteristic pros and cons of these 
measurement tools (such as ease of use, burden, range and 
ability to capture FITT parameters) have been discussed in 
healthy individuals [8,12,13,14,15] older adults [9], 
wheelchair users [16] and people with neuromuscular 
diseases [17]. However, it is not known which measures 
might be most suitable for the assessment of physical 
activity specifically in adults with muscular dystrophy 
which is characterised by progressive weakness, heterogeneous 
presentations and variable function. It is therefore important 
to ascertain the generalizability and interpretability of 
physical activity measures in adults with muscular dystrophy 
to aid selection of appropriate measurement tools. 
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Figure 2. Framework of measurement characteristics and measurement properties. Diagram created by author (SRL) based on COnsensus-based 
Standards for the selection of health Measurement INstruments (COSMIN) checklist [28] and manual taxonomy and definitions [10] 
The measurement properties (reliability, responsiveness 
and validity) of physical activity measures have also been 
investigated in multiple studies in various populations, 
including other neurological, rheumatological, oncological 
or pulmonary conditions and healthy, elderly, disabled or 
cognitively impaired individuals [9,12,13,17]. However, 
cumulative evidence is inconclusive due to conflicting 
reports, varied study design, diversity of measures and 
lack of consensus about gold standard criterion measures. 
Furthermore, reliability, responsiveness and validity of 
physical activity measures established in other populations 
may not be transferable to adults with muscular dystrophy 
who may have very different muscle, metabolic and 
cardiac functioning [18,19,20,21]. Thus, the measurement 
properties of physical activity measures when used  
with adults with muscular dystrophy remain unclear.  
To the authors’ knowledge, this is the first review to 
examine population specific evidence for the reliability, 
responsiveness and validity of physical activity measurement 
in adults with muscular dystrophy. 
The objectives of this review were, firstly, to identify 
direct and indirect physical activity measures used to 
assess adults with muscular dystrophy in a range of  
study designs and to describe their generalizability and 
interpretability. Secondly, to appraise the evidence of 
reliability, responsiveness and validity for physical activity 
measures in studies which included adults with muscular 
dystrophy. Finally, based on a narrative synthesis, to make 
recommendations, where possible, for the selection of 
suitable physical activity measurement tools for use with 
adults who have muscular dystrophy. 
2. Methods 
The protocol was registered on PROSPERO in July 2017 
(Registration Number CRD42017070514) and follows the 
Preferred Reporting Items for Systematic Reviews and 
Meta-Analyses guidelines [22].  
2.1. Search 
The search was conducted in 2 phases. Phase 1 was 
designed to identify physical activity measures used to 
assess adults with muscular dystrophy and to describe 
their generalizability and interpretability. Phase 2 was 
designed to identify and appraise evidence for their 
reliability, responsiveness and validity. 
In July 2017 (phase 1) and January 2018 (phase 2) the 
following databases were searched: Medline (1946-2017/8), 
Embase + Embase Classic (1947-2017/8), Global Health 
(1973-2017/8), PsycINFO (1806-2017/8), HMIC Health 
Management Information Consortium (1979-2017/8) and 
Journals @ Ovid Full Text. In phase 1, Ovid search terms 
were expanded from ‘muscular dystrophy’, ‘physical 
activity’ and ‘measure’. In phase 2, the search strategy 
was informed by the previous search results and additional 
‘measurement property’ search terms were added. (For 
full search see supplementary material appendix I.) 
2.1.1. Study Selection 
Studies were selected by 3 reviewers using the 
eligibility criteria listed in Table 1. (In phase 1: SRL and 
CW (10% sample); in phase 2: SRL, FS and CW (10% 
sample)). Disagreements were resolved by consensus 
discussion at this stage and throughout (arbitrated by CW). 
Studies of any design were included if they had 
measured physical activity in any adult(s) with muscular 
dystrophy. Only studies where the measurement of 
activity spanned more than 10 minutes were included as 
shorter bouts of activity are not considered to contribute to 
recommended daily activity tallies [23,24,25]. The FITT 
framework (see Figure 1) was applied to ensure that only 
those intending to quantify physical activity overall or in 3 
or more FITT parameters were included. When several 
reports pertained to the same study, the most recent or 
comprehensive article in terms of physical activity 
measurement was selected. In phase 2, inclusion was 
further limited to full text articles that evaluated reliability, 
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responsiveness and validity. A scarcity of physical activity 
measurement evaluation studies in adults with muscular 
dystrophy was anticipated. So, inclusion encompassed not 
only studies that overtly reported validity, reliability and 
responsiveness but also those that included hypothesis 
testing which incidentally indicated measurement 
properties of physical activity measures. 
2.1.2. Data Extraction 
The data extraction form was developed a priori, 
customised from previously published extraction tools 
[26,27] (see supplementary material appendix II). In 
phase 1, descriptive data were extracted by a single 
reviewer (SRL). In phase 2, 2 reviewers (SRL and FS) 
independently extracted the data. 
2.1.3. Methodological Quality 
In phase 1, methodological quality assessment was 
unnecessary because data were descriptive only. In phase 
2, methodological quality was independently assessed by 
2 reviewers (SRL and FS) using the COSMIN guidelines 
[28] to rate evidence supporting measure reliability, 
responsiveness or validity as excellent, good, fair or poor. 
2.1.4. Synthesis 
In phase 1, physical activity measures identified were 
described, listed and categorised. Their generalizability 
was quantified in terms of number of studies, number of 
participants, demographics (including age range, gender, 
diagnoses and mobility) and environment. Their 
interpretability was considered in terms of FITT 
measurement scope (i.e. capture of how often and how 
long different activities were carried out for and at what 
intensity, for example light, moderate or vigorous), 
timeframe, mode, metric and range of scores. In phase 2, 
evidence, and its methodological quality rating, for the 
validity, reliability and responsiveness of physical activity 
measures was listed for each included study. A narrative 
synthesis was carried out, considering the strength and 
consistency of evidence. 
Table 1. Inclusion and exclusion criteria 
Inclusion Exclusion 
Participants 
Study cohorts including at least 1 adult (aged over 18 years*) with a 
diagnosis of Muscular Dystrophy including:  
 Limb Girdle Muscular Dystrophy (LGMD)  
 Myoshi Myopathy (MM) 
 Becker’s Muscular Dystrophy (BMD) 
 Fascioscapulohumeral Muscular Dystrophy (FSHD) 
 Oculopharangeal Muscular Dystrophy (OPMD) 
 Myotonic Dystrophy or Dystrophia Myotonica (DM) 
 Unspecified Muscular Dystrophy (MD) 
 Duchenne Muscular Dystrophy (DMD) 
 Adult Congenital Muscular Dystrophy (CMD) 
Non-human subjects or in vitro cell cultures 
Cognitive impairment, pediatric*  
Other causes of muscle wasting including:  
 Inflammatory myopathies 
 Metabolic myopathies 
 Other neuromuscular conditions (e.g. Spinal Muscular Atrophy, bulbospinal 
muscular atrophy (Kennedy’s disease), Cerebral Palsy, Spina Bifida, Multiple 
Sclerosis)  
 Muscle wasting secondary to other conditions (e.g. Amputation, Cancer, 
Stroke, Spinal Cord Injury, Rheumatoid Conditions, immobility) 
Intervention 
Physical activity including free-living activities or prescribed exercise, 
lasting 10 minutes or more, where physical activity can be defined as:  
 “Behaviour that involves human movement, resulting in 
physiological attributes including increased energy expenditure and 
improved physical fitness” (page S11) [7] or 
 “Any bodily movement produced by skeletal muscles that requires 
energy expenditure beyond resting expenditure” (page 3109) [6] and 
“the execution of a task or action by an individual” (page 577) [121]  
No physical activity  
The following types of activities:  
 activity lasting less than 10 minutes (or for an undisclosed time period) 
 Activities during therapy sessions 
 Activities performed at relative rest (e.g. sleep or nocturnal movements, 
resting activity, mouth or tongue exercises, small muscle hand exercises and 
pulmonary muscle training) 
 Functional activity milestones (e.g. interval analysis of loss of ambulation) 
Comparison and outcomes 
Studies reporting measurement of physical activity. 
Measurement encompassing 3 or more FITT parameters by a battery of 
measurement approaches or encompassing overall physical activity 
measurement for:  
 An evaluation of measurement properties 
 A primary or secondary outcome 
 Assessment of compliance 
 An independent variable 
 A demographic characteristic 
Studies with no measurement of physical activity reported, or measurement 
period lasting under 10mins. 
Studies reporting only about measures:  
 Of activity limitation i.e. ease/difficulty of performing activities (including 
quality of life measures) 
 Of fitness (e.g. from a single time point, such as maximal oxidative 
capacity, maximal workload or exertion rating) 
 Used to capture only resting activity without corresponding active 
measurement 
Study Design 
Peer reviewed articles† of any methodological design including:  
Measure evaluation studies 
Experimental studies (randomised designs) 
Observational analytic studies (pre/post, comparison) 
Descriptive (longitudinal, cross-sectional, case studies) 
Prospective or retrospective 
Bibliographies of relevant full texts were hand searched for pertinent articles 
and authors, but the following were excluded:  
Reviews (systematic or narrative) 
Journal letters/ correspondence/ consensus summaries 
Unpublished data 
Articles not available in English language 
* If age range was not reported, a conservative estimated range was extracted as mean ±1 standard deviation to account for skewed distribution towards 
lower ages in pediatric studies. † In phase 1 abstracts and protocols were included unless superseded by a full text article; in phase 2 only full text 
articles were included. 
4 Journal of Physical Activity Research  
 
Figure 3. Study selection schematics for phase 1 (A) and phase 2 (B) 
3. Results 
3.1. Phase 1 
Study selection is summarised in Figure 3a. Agreement 
between reviewers (SRL and CW) was 90% and 87% for 
abstract and full text screening respectively, with full 
agreement after consensus discussion. Included articles 
are listed and described in Table 2; 63 physical activity 
measures were identified (see Table 3 and 3a supplement). 
3.1.1. Generalizability 
Activity measurement was generalizable across gender, 
mobility from independent walking to wheelchair use, age 
range from teenager to elderly and amongst different 
muscular dystrophy diagnoses. Myotonic Dystrophy and 
Facioscapulohumeral Dystrophy were the most commonly 
assessed. Indirect measures were used to assess larger 
numbers of participants than direct measures, particularly 
standardised questionnaires (n=1567). Of the direct 
measures, the greatest number of participants were 
assessed using accelerometry (n=731). Many studies used 
standardised questionnaires, non-standardised diaries, 
heartrate monitoring, direct observation and accelerometry 
(15 studies [29-43] including 3 RCTs [29,33,41], 18 studies 
[29,33,40-41,44-57] including 4 RCTs [33,41,44,48], 15 
studies [29,33,40,44-45,48-49,50-55,58-59] including 5 
RCTs [29,33,44,48,58], 13 studies [29,44,48,51,58-66] 
including 4 RCTs [29,48,58,65] and 13 studies 
[29,33,37,41,44,46,53,61,67-71] including 6 RCTs 
[29,33,41,44,67,68] respectively). Whereas, single and 
sub-scale activity measures, calorimetry and positioning 
systems were the least widely used in the fewest 
participants.  
Free-living physical activity was most usually assessed, 
especially by questionnaires, diaries, continuous heartrate 
monitoring and accelerometry. However, prescribed 
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activities were also assessed at home and in other 
environments, including the gym, sports pitch and 
laboratory, where activity was monitored by indirect 
calorimetry, periodic heartrate monitoring and some 
training logs. 
The most generalizable tools within each category,  
used in the most studies and participants with the  
widest spectrum of demographics, included 2 standardised 
questionnaires (the International Physical Activity 
Questionnaire (IPAQ), the Physical Activity Scale  
for Individuals with Physical Disabilities (PASIPD)), 
activity logs, Polar heartrate monitors and triaxial, ankle 
accelerometers (although, the only accelerometer used to 
assess non-ambulant participants was wrist-worn [46]). 
Table 2. Description of 53 included studies 
Design (n) / 
Description* 
 
Citation 
 
Condition (n) 
Age 
range 
Gender 
(m/f) 
 
Phase 
Experimental (9) 
RCT 
Andersen et al., 2017 [29] FSHD (12) 26-67 9/3 1 & 2 
Andersen et al., 2015a [33] FDHD (41) 22-65 21/20 1 
RCT (crossover) 
Voet et al., 2014 [44] FSHD (77) 20-79 37/40 1 & 2 
van der Kooi et al., 2007 [65] FSHD (65) 27-51† 40/25 1 & 2 
RCT (protocol) 
Veenhuizen et al., 2015 [58] FSHD (estimated 17) N/R N/R  1 
Van Engelen et al., 2015 [68] DM (296) N/R N/R 1 
RCT (pilot) 
Kierkegaard et al., 2011b [48] DM (35) 20-65 15/20 1 & 2 
Dawes et al., 2006 [41] BMD (4), FSHD (3), LGMD (4), CMD (1), DM (4) 18-81 10/6 ‡ 1 & 2 
RCT (2° analysis) Janssen et al., 2016 [67] FSHD (31) 39-67† 22/9 1 & 2 
Observational analytic (26) 
Cross-sectional 
Jacques et al., 2017 [30] BMD (21) 26-52† 21/0 1 & 2 
Heutinck et al., 2017 [72] DMD (estimated 30) 16-26† 30/0 ‡ 1 & 2 
McCrory et al., 1998 [55] DM (9), FSHD (3), BMD (1) 29-63† 8/5 ‡ 1 & 2 
Cohort 
Brun et al., 2017 [122] LGMD (41) 12-72 20/21 1 
Smith et al., 2016 [31] MD (282) N/R N/R 1 & 2 
Morse et al., 2016 [32] FSHD (11), BMD (11), LGMD (9), DMD (11) 18-59 42/0 1 & 2 
Andersen et al., 2015b [62] DM (7), FSHD (6), LGMD (2), BMD (2) 18-52 10/7 1 
Vissing et al., 2014 [45] LGMD (4), MM (2) 39-54 4/2 1 
Dahlqvist et al., 2014 [63] BMD (4) 26-32 4/0 1 
Andersen et al., 2013 [64] BMD (5), FSHD (5), LGMD (4) 20-58 12/2 1 & 2 
Sveen et al., 2008 [49] BMD (11) 28-36† 11/0 1 
Sveen et al., 2007 [50] LGMD (9) 43-53† 6/3 1 
Wintzen et al., 2007 [123] DM (13) 29-57† 5/8 1 
Wiles et al., 2006 [70] DM (13) 44-48† N/R 1 & 2 
Aitkens et al., 2005 [54] DM (4), LGMD (3), FSHD (1) 47-54† N/R 1 & 2 
Kilmer et al., 2005 [53] LGMD (8), DM (4), FSHD (2), BMD (2) 37-63† 10/6 ‡ 1 & 2 
Orngreen et al., 2005 [52] DM (12) 21-58 9/3 1 
Olsen et al., 2005 [51] FSHD (8) 18-55 4/4 1 
Taivassalo et al., 1999 [66] LGMD (4), MD (3), OPMD (2), DM (1) 29-63 5/5 1 
Wright et al., 1996 [56] DM (5), LGMD (1) 28-40 4/2 1 
Aitkens et al., 1993 [57] DM (12), LGMD (3), FSHD (2) 25-55† 11/6 ‡ 1 
Florence and Hagberg, 1984 [74] LGMD (3), CMD (2), FSHD (1) 21-40 6/0 1 
Cohort (protocol) Lassche et al., 2013 [37] FSHD (predicted 14), OPMD (predicted 14) N/R N/R 1 
Case control 
 
Brady et al., 2014 [124] DM (63) 26-57† 26/37 1 
Angelini et al., 2011 [125] MM (13), LGMD (3) 16-50 12/4 ‡ 1 
Kalkman et al., 2007 [69] DM (70), FSHD (60) 22-61 75/55 ‡ 1 & 2 
Descriptive (18) 
Cross-sectional  
(Evaluative) 
Martin and Whalen, 2012 [75] MD (4) 13-64† 2/2 ‡ 1 & 2 
Busse et al., 2004 [71] MD (10) 39-65† 6/4 1 & 2 
Washburn et al., 2002 [42] MD (estimated 25) N/R N/R 1 & 2 
Kimura et al., 2014 [46] DMD (12) 10-19 12/0 1 & 2 
Chen et al., 2014 [47] MD (1) 46 0/1 1 & 2 
Cross-sectional 
Barfield et al., 2016 [60] MD (4) 7-63 N/R (4) 1 & 2 
Matsuda et al.,2015 [34] MD (332) 18-65 140/192 1 
Rosenberg et al., 2013 [36] MD (321) 20-85 136/185 1 & 2 
Shimizu-Fujiwara et al., 2012 [126] DMD (6) 18-24 6/0 1 
Komaki et al., 2011 [127] DMD (26) 14-38 26/0 1 
Kierkegaard et al., 2011a [38] DM (70) 19-70 29/41 1 & 2 
Harris et al., 2010 [73] MD (1) 36-50 N/R 1 
Phillips et al., 2009 [40] FSHD (5), DM (5), LGMD (1) 32-56† 3/8 ‡ 1 & 2 
Longmuir and Bar-Or, 2000 [43] MD (12) 15-20 6/6 1 & 2 
Cross-sectional 
abstracts  
Eichinger et al., 2013 [35] DM (107) N/R 57/50 1 
Phillips and Marr, 2009 [39] DM (97), LGMD (82), FSHD (68) 24-65† N/R 1 
Meilleur et al., 2015 [61] CMD (11) N/R N/R 1 
Case study Pasotti et al., 2014 [59] FSHD (1) 43 0/1 1 
*Classified according to Centre for Evidence-Based Medicine study design guidelines [128]. † Range calculated by mean (or median) ± 1 standard 
deviation (or confidence interval) in the absence of reported range. ‡ Estimated age range from proportion of larger sample. Abbreviations: RCT – 
Randomized Controlled Trial; FSHD – Facioscapulohumeral Dystrophy; DM – Dystrophia Myotonica (Myotonic Dystrophy); BMD – Becker’s 
Muscular Dystrophy; DMD – Duchenne’s Muscular Dystrophy; LGMD – Limb Girdle Muscular dystrophy; MD – Muscular Dystrophy (type 
unspecified); MM – Miyoshi-like Myopathy; OPMD – Oculopharyngeal Muscular Dystrophy; CMD – Congenital Muscular Dystrophy; N/R – not reported. 
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Table 3. List of 63 measures used to assess adults with muscular dystrophy 
Indirect Measures (27) 
IPAQ International Physical Activity Questionnaire [29,31,34-37] 
PASIPD Physical Activity Scale for Individuals with Physical Disabilities [32,39,42] 
B-PAR  Bouchard Physical Activity Record [33] 
EPIC Norfolk Physical Activity Questionnaire [40] 
PASE  Physical Activity Scale for the Elderly [41] 
GLTEQ Godin Leisure Time Exercise Questionnaire [36] 
CFS The Canada Fitness Survey [43] 
BPAQ Bone-specific Physical Activity Questionnaire [30,32] 
FAI  Frenchay Activities Index [38] 
PSDQ – activity Subscale of the Physical Self-Description Questionnaire [75] 
ACS – participation  Subscale/specific ranking of Activity Card Sort [58]  
FPACQ – transport  Subscale of the Flemish Physical Activity Computerized Questionnaire [72] 
MAQ – activity Subscale of the Modifiable Activity Questionnaire [72] 
PAGS Physical Activity Grading Scale (single scale) [38,48] 
ACR Activity Change Rating (single scale) [51-52] 
AI 1-5 Activity Increment 1-5 (single scale) [123] 
DOA Daily Observation of Activity (single scale) [65] 
Diary Physical activity recorded in a diary [40,46,54,55] 
Diary (electronic) Physical activity recorded in computer software [47]  
Dairy + DQ Physical activity recorded in a diary with a direct quantifier (step count) [53] 
Log Training log [29,33,48-49,51-52] 
Log + Q Training log with a self-report quantifier (rating of perceived exertion) [41] 
Log + D Training log with direct quantifiers (heartrate, revolutions per minute) [45,50] 
Log + Q + D Training log with rating of perceived exertion and direct quantifiers (HR, workload) [44,56] 
Log + Q (‘phone) Training log by telephone with self-report quantifiers (rating of perceived exertion and repetitions) [57] 
Interview Study specific interviews [33,73,124,125] 
Survey Study specific survey [122]  
Direct Measures (36) 
Pedometer Unspecified (waist) [41] 
Pedometer Yamax Digiwalker (waist, uniaxial) [53] 
Pedometer Omron Walking Style Pro (waist, triaxial) [29] 
Actometer Unspecified (ankle) [37] 
Actometer StepWatch™ (ankle, biaxial) [70-71] 
Actometer Actilog V3.0 (ankle, triaxial) [44,67,69] 
Actometer Motionlogger Watch (wrist, triaxial) [46] 
Actometer Actigraph GTX3 (wrist, triaxial) [61] 
Actometer Kinesense GeneActiv (wrist, triaxial) [68] 
Actometer SenseWear Pro (arm, biaxial plus temperature sensing) [33] 
Pulsewatch Unspecified [33,58] 
Pulsewatch Polar (model not specified) [51-52] 
Pulsewatch Polar RS400 [59] 
Pulsewatch Polar (S610) [29,48] 
Pulsewatch Polar (Accurex) [49-50] 
Pulsewatch Polar (FT40) [45] 
Pulsewatch Polar (Vantage XL) [53-55] 
Pulsewatch Garmin Forerunner 50 [44]  
Heart monitor Polar (model not specified) [40] 
Counting Directly observed step counts [61] 
Spectating Directly observed competitive sport [60] 
Video + D Supervision via Skype with a direct quantifier (workload0 [59] 
Supervision Directly observed supervised exercise [29,51,58,65] 
Supervision + R Directly observed exercise with self-report quantifier (rating of perceived exertion) [48] 
Supervision + D Directly observed exercise with a direct quantifier (heartrate) [66,74] 
Supervision + R + D Directly observed exercise with rating of perceived exertion and direct quantifiers (heartrate, workload) [44,62,63,64] 
Indirect calorimetry Gaseous exchange analyser (K4b2) [60] 
Indirect calorimetry Gaseous exchange analyser (Oxycon Mobile) [60] 
Indirect calorimetry Gaseous exchange analyser (Quark b2, Cosmed) [64] 
Indirect calorimetry Gaseous exchange analyser (2900 Metabolic System) [53-55] 
TEE by DLW Total Energy Expenditure calculated using Double -Labelled Water [127] 
TEE by diet Total Energy Expenditure calculated using dietary intake [126-127] 
TEE by HR Total Energy Expenditure from monitoring heartrate, oxidative capacity equivalence and factorial diaries [53-55] 
PAL Physical Activity Level index calculated from total / resting energy expenditure [53,54,126,127] 
GPS UbiTrak Global Positioning System tracker [47] 
GPS Participation and Activity Measurement Global Positioning System tracker [73] 
For full measure descriptions and categorizations, see Table 3a in the supplementary material. 
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3.1.2. Interpretability 
Indirect measures collected activity spanning 3 days to 
a year (or lifetime), some in real-time, including activity 
diaries of 3 days to 6 months, and others by recall, 
including standardised questionnaires often over 7 days. 
Whereas, all direct measures recorded activity in real-time 
from 10 minutes to 6 months. Most recording periods 
lasted 1-14 days, except for direct observation, periodic 
heartrate monitoring and indirect calorimetry which were 
conducted over shorter timeframes of between 10-90 
minutes. There was great variability in the metrics of 
activity measures, making it difficult to compare activity 
measurement ranges (see table 3 and 3a supplement). 
Standardised questionnaires and diaries had the best  
scope to quantify discrete FITT parameters; whereas 
direct measures like accelerometry and energy expenditure 
calculations were usually concerned with overall physical 
activity.  
Interpretability was boosted by using multiple physical 
activity measures in 32 included studies [29,32-33,36-38, 
40-41,44-46,48-60,62-66,72-74], including 7 of the 9 
RCTs [29,33,41,44,48,58,65]. Multiple measures increased 
the scope of physical activity measurement in terms of FITT  
in 29 studies [29,33,38,40-41,44-46,48-60,62-66,72-74] and 
ocomplementary indirect and direct measures were employed 
in 29 studies [29,33,37,40-41,44-58, 60, 62-66,72-74]. 
Table 4. Study characteristics of studies and evaluated measures included in phase 2 
Author / 
COSMIN 
Study Description Measure(s) Measurement properties 
Washburn 
et al., 2002 
 
GOOD 
Observational descriptive 
cross-sectional study for 
measure evaluation of the 
Physical Activity Scale 
for Individuals with 
Physical Disabilities in 
372 disabled people [42] 
PASIPD  
 
(Physical Activity Scale 
for Individuals with 
Physical Disabilities) 
Reliability 
Internal consistency was demonstrated by significant item correlations with 
total score (r=0.20-0.67 for all items, p<0.05) and factor analysis of 5 clusters 
(accounting for 63% of variance in total scores, with Cronbach’s alpha 
ranging from .37 to .65) 
Construct validity 
Discriminative validity was demonstrated by extreme group differences in 
PASIPD score between young versus old (mean difference = 8.1, p<0.001), 
self-rated health excellent versus fair/poor (mean difference = 11.9, p<0.001), 
attendant care versus those without (mean difference = 11.9, p<0.001) and 
self-rated physical activity (mean difference = 17.5, p<0.05) 
Martin and 
Whalen, 
2012 
 
FAIR 
 
Observational descriptive 
cross-sectional study for 
measure evaluation of the 
Physical Self-Description 
Questionnaire in 50 
disabled people [75] 
PSDQ – Activity  
 
(Physical activity 
subscale of the Physical 
Self-Description 
Questionnaire) 
Reliability 
Internal consistency of subscale was high (Cronbach’s alpha =0.85) 
Construct validity 
Convergent validity demonstrated by significant moderate to low associations 
with certain PSDQ subscales (sport confidence r=0.56, flexibility r=0.50, 
coordination r=0.43, endurance r=0.33 (all p<0.05), strength r=0.62 and 
multiple regression analysis beta=0.37, r2=0.47, p=0.03). Convergent validity 
was not demonstrated with the other subscales of the PSDQ. 
Kimura et 
al., 2014 
 
POOR 
Observational descriptive 
cross-sectional study for 
measure evaluation of the 
utility of a wrist actigraph 
for estimating muscle 
strength in 22 people with 
Duchenne’s Muscular 
Dystrophy [46] 
Actometer 
 
(Motionlogger Watch; 
triaxial wrist actigraph, 
Ambulatory Monitoring, 
Ardsley, NY, USA)  
Construct validity 
Discriminative validity was demonstrated by extreme group differences in 
Actigraph zero crossing mode (ZCM) and Actigraph proportional integration 
mode (PIM) scores between ambulant and non-ambulant people with DMD 
(Wilcoxon rank-sum test, ZCM p<0.001, mean difference 44 counts per 
minute, PIM p<0.001, mean difference 36406 bits) 
Convergent validity was demonstrated by weak to moderate significant 
correlations of Actigraph ZCM and PIM scores with 6-minute walk distance 
(6MWD) and knee extension strength measured using handheld 
dynamometry (Spearman’s, ZCM with 6MWD, rho = -0.44, p<0.01, ZCM 
with knee extension strength, rho = 0.25, p<0.01, PIM with 6MWD, rho = 
0.58, p<0.01, PIM with knee extension strength, rho = 0.63, p<0.01) 
Chen et al., 
2014 
 
POOR 
 
Observational descriptive 
cross-sectional study for 
measure evaluation of a 
novel movement tracking 
system in 5 disabled 
people [47] 
UbiTrak (GPS) 
 
(Global Positioning 
System and Wireless 
Fidelity tracker) 
Reliability 
Measurement error was demonstrated as acceptable by good to strong 
agreement between UbiTrak and electronic activity diaries (62-87% 
agreement) 
Busse et 
al., 2004 
 
POOR 
 
Observational descriptive 
cross-sectional study for 
measure evaluation of the 
StepWatch in 10 people 
with primary muscle 
disease and comparison 
to healthy controls [71] 
Actometer 
 
(StepWatch™, biaxial, 
ankle step activity 
monitor (Cymatech, 
USA) 
Reliability 
Test-re-test reliability demonstrated for 7-day mean step count 1-3 weeks 
apart (ICC=0.86) and for peak 30-minute step count and average 20, 30 and 
60-minute step counts (ICC=0.82-0.95) 
Construct validity 
Discriminative validity was demonstrated by extreme group differences in 
mean 7-day step count between mobility impaired and healthy (independent 
t-test, mean difference = 2365, p=0.001) 
Convergent validity was demonstrated by significant correlation between gait 
speed and mean 7-day step count (Pearson’s, r = 0.45, p= 0.01) but not 
demonstrated with the Rivermead Mobility Index. 
For incidental measurement properties see table 4a in the supplementary material. Abbreviations: ICC – intraclass correlation coefficient; DMD – 
Duchenne’s Muscular Dystrophy; ZCM – zero crossing mode; PIM – proportional integration mode; 6MWD – 6-minute walk distance. 
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3.2. Phase 2 
Study selection is summarised in Figure 3b. Agreement 
between the 2 reviewers (SRL and FS) was 86%, 87%,  
91% and 86% for abstract, full text screening, data 
extraction and COSMIN ratings respectively, with full 
agreement after consensus discussion. Evidence for the 
reliability, responsiveness and validity of 32 physical 
activity measures is listed in Table 4 (and 4a supplement). 
Only 5 included studies [42,46,47,71,75] had as their primary 
objective the evaluation of measurement properties of a 
physical activity measure; the remaining 21 articles were 
included for incidental measurement properties from 
hypothesis testing relating to other objectives. No studies 
were rated as excellent; 2 were rated as good [36,42], 12 
as fair and 11 as poor. This was largely due to low sample 
sizes and incidental measure evaluation. 
3.2.1. Reliability and Responsiveness 
There was very little evidence for reliability or 
responsiveness testing of any physical activity measures. 
Of the indirect measures, there was good quality evidence 
of internal consistency of the PASIPD from an evaluative 
study including 372 participants, an estimated 7% of whom 
had muscular dystrophy [42]. There was fair quality 
evidence of internal consistency of the Physical Self-
Description Questionnaire (PSDQ-S) from an evaluative 
study including 50 participants, 8% of whom had 
muscular dystrophy [75]. There was also incidental report 
of moderate to high test-re-test reliability of the Canada 
Fitness Survey (CFS) [43,76]. 
Of the direct measures, there was poor quality evidence 
of good test-re-test reliability of the StepWatch [71] 
accelerometer and moderate measurement error of Ubitrak 
(a Wi-Fi and GPS (Global Positioning System) movement 
tracker) [47]. There was poor quality, incidental evidence 
of inter-rater reliability between indirect calorimetry 
gaseous analysers, K4 b2c and Oxycon Mobiled [60] and 
responsiveness of a pedometer compared to the Physical 
Activity Scale for the Elderly was tenuously indicated, as 
neither detected significant changes in physical activity 
post intervention [41]. 
3.2.2. Validity 
There was a small amount of evidence supporting the 
validity of 2 indirect measures (see table 4). The strongest 
evidence was for the PASIPD, which had good quality 
evidence of significant discriminative validity between 
extreme groups [42] and some incidental, consistent, fair 
quality evidence for concurrent validity [30,32]. There 
was also fair quality evidence for convergent validity of 
the PSDQ-S activity subscale [75]. Based on incidental 
findings only, there was some cumulative evidence  
for 2 other questionnaires: The Bone-specific Physical 
Activity Questionnaire (BPAQ), which had consistent, fair 
quality evidence for discriminative validity [30,32] and 
convergent validity [32] and the IPAQ, which had good 
quality evidence for convergent validity [36] and mixed, 
poor quality evidence for [29] and against discriminative 
validity [31]. Evidence for the validity of other direct 
measures was even more sparse. However, incidental 
validity of diaries was tentatively indicated, including low 
quality evidence of discriminative validity for an activity 
diary [54,55] and convergent validity of a training log  
[48]. 
There was no good quality evidence supporting the 
validity of any direct measures. However, there was some 
collective, low-quality evidence concerning accelerometry 
and heartrate monitoring. There was cumulative, 
predominantly incidental, evidence of discriminative and 
convergent validity of accelerometry, which was stronger 
for triaxial accelerometers (Omron [29], Motionlogger [46] 
and Actilog [67,69]) than biaxial (StepWatch [70,71]) or 
uniaxial devices (Yamax digi-walker [53]) and for ankle 
[44,67,69,70,71] rather than trunk [29] or wrist [46] 
placement. There was incidental, consistent evidence for 
discriminative validity [40,54] and convergent validity [48] 
of Polar heartrate monitors and mixed evidence for [54,55] 
and against [53] discriminative validity of heartrate 
monitoring used with indirect calorimetry equivalence to 
estimate total energy expenditure. 
4. Discussion 
The main finding of this systematic review is that 
physical activity has been measured in numerous and 
various ways in a range of 53 studies assessing adults with 
muscular dystrophy. There is no consensus about the most 
generalizable or interpretable activity measurement tools 
for this group. Furthermore, evidence is limited about measure 
reliability, responsiveness and validity for the assessment 
of physical activity in adults with muscular dystrophy. 
Only 5 studies overtly evaluated the measurement properties 
of physical activity measures and none have provided high 
quality evidence of reliability, responsiveness and validity. 
4.1. Direct Measures 
Despite the paucity of evidence for reliability, 
responsiveness and validity of direct measures of physical 
activity in adults with muscular dystrophy, tools like 
accelerometry and heartrate monitoring might have 
potential. As demonstrated in the literature [9,14,15,16,77] 
and by the studies identified in this review, accelerometry 
and heartrate monitoring are both fairly generalizable and 
interpretable. Accelerometry can capture free-living activity 
over the medium (days/weeks) to long-term (months) and 
can detect frequency, absolute intensity, and timing, also 
yielding an overall quantification of physical activity. 
Although accelerometry cannot discern relative exertion 
or type of activity, it is adaptable, relatively inexpensive, 
and unobtrusive. In terms of measurement properties, 
tentative construct validity of accelerometry has been 
indicated in this review, with the best evidence in support 
of triaxial devices. Multi-plane movement detection, 
although not integral for regular walking, may be more 
suited to irregular torsions [78], characteristic of abnormal 
mobility in adults with muscular dystrophy [79]. Furthermore, 
for healthy people and those with chronic diseases, multi-
axial devices have also demonstrated stronger criterion 
validity and lower measurement error than uniaxial 
devices [80]. Similarly, the triaxial GENEActiv has been 
validated over 6 minutes or less in adults with myotonic 
dystrophy [81] with construct validity supported incidentally 
in a high quality RCT [82] (too recent for inclusion in this 
systematic search) and the biaxial StepWatch has been 
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extensively validated in ambulant people with Multiple 
Sclerosis, Parkinson’s Disease and children with Duchenne’s 
Muscular Dystrophy [71,83,84,85]. In contrast, criterion 
validity was reportedly low and measurement error 
unacceptably high for the uniaxial Digi-walker over 2 
minutes, in ambulant adults with neuromuscular diseases, 
including muscular dystrophy [86]. In this review, there 
was more evidence for generalizability of accelerometer 
placement on the ankle than the trunk or wrist, although it 
came only from ambulant participants; whereas, wrist 
placement better encompassed a range of mobility 
including wheelchair users [46]. In the literature, wrist 
accelerometry has been linked to non-ambulant assessment 
[87] and lower measurement error at slow walking speeds 
[88] which may become relevant as muscular dystrophy 
progresses [79]. Thus, triaxial accelerometry, placed at the 
ankle or wrist, represents a potential tool for the assessment 
of physical activity in adults with muscular dystrophy, 
subject to establishing robust reliability, responsiveness 
and validity in both ambulant and non-ambulant. 
Heartrate monitoring may also have potential, particularly 
for monitoring compliance with, and recording intensity of, 
prescribed exercise interventions in adults with muscular 
dystrophy. In this review there were tentative indications 
for construct validity of Polar devices. They are generalizable 
and can record frequency, timing and relative intensity of 
exertion, which is particularly useful for quantifying prescribed 
activity [89]. However, heartrate monitors cannot differentiate 
between activity and emotional heartrate responses, thus 
there is a requirement to collect supplementary information, 
such as a diary or predetermined personal activity zone 
heartrates [54,55]. In addition, reduced heartrate variability in 
muscular dystrophies [20] might impact the interpretation 
of heartrate comparisons, especially relative to predicted 
values. Higher resting and lower submaximal/maximal 
heartrates have been reported in Duchenne’s Muscular 
Dystrophy [83] and increased sympathetic drive  
with progressive parasympathetic dampening in 
Facioscapulohumeral Dystrophy [21]. Similar caution is 
required for energy expenditure extrapolations from 
heartrate or accelerometry data due to potentially altered 
metabolic functioning in adults with muscular dystrophy 
[18,19,90,91]. Thus, it is advisable to report actual recorded 
heartrate in beats per minute, or absolute step counts, and 
to treat extrapolated values with circumspection.  
4.2. Indirect Measures 
The same reservations about energy expenditure 
extrapolations must be applied to indirect measures that 
estimate metabolic expenditure. Additional caution is also 
necessary when interpreting questionnaire scores due to 
the potential for self-report, re-call and/or social desirability 
bias, which usually produce overestimations [8]. However, 
indirect, self-report measures of physical activity for 
adults with muscular dystrophy are widely generalizable, 
inexpensive, acceptable and easy to use [9,11,12]. 
Several standardized questionnaires were identified as 
having potential in this review. The PASIPD had the 
strongest evidence supporting its reliability and validity 
which is consistent with evidence from other populations 
including strong test-re-test reliability [92,93], discriminative 
validity [94] and low [92,93,95,96] to moderate [94] 
criterion validity. However, significant overestimation 
measurement error has been reported [95]. In terms of 
interpretability, PASIPD comprehensively covers FITT 
and is sensitive to disabled and low-level activities, although 
it is unsuitable for comparisons with non-disabled populations. 
The IPAQ, BPAQ and PSDQ-S are suitable for comparison 
with other populations; the BPAQ and PSDQ-S are 
situation specific to bone health [97] and self-perception 
[98] respectively. The IPAQ is the most generalizable 
questionnaire identified in this review and various 
versions are available including short, long and modified 
versions (more sensitive to lower activity intensities  
and non-ambulant mobility [99,100]). In this review,  
the validity of the IPAQ was inconclusive. However, 
measurement properties established in other populations 
include strong test-re-test reliability [23,101,102] moderate 
responsiveness [103,104], low [23,100,101,103,104] to 
moderate [23,105] criterion and convergent [105] validity 
and predominantly overestimation measurement error 
[104,106]. Thus, if acceptable reliability, responsiveness 
and validity can be established and energy expenditure 
scores are treated circumspectly, both the PASIPD and 
IPAQ have potential for the assessment of physical 
activity in adults with muscular dystrophy. 
Activity diaries also have potential as generalizable and 
interpretable activity measures, especially those designed 
to span FITT which are often used for prescribed activity 
monitoring. In addition, diaries might have potential as an 
adjunctive activity measure. Supplementary activity  
logs have been shown, for example, to mitigate IPAQ 
overestimation [107] and to improve criterion validity and 
measurement error [104]. Diaries have also been 
advocated alongside direct activity measures [14,15] and, 
in this review, diaries appeared to strengthen interpretation 
of heartrate monitoring and indirect calorimetry 
equivalence [53,54,55]. Activity diaries are, therefore, not 
only useful for monitoring prescribed activity, they may 
have an application as adjuncts to enhance interpretability 
of free-living physical activity measurement. 
4.3. Implications 
Clearly, all physical activity measures have limitations, 
both general and specific to adults with muscular dystrophy. 
These must be considered in study design and some authors 
have compiled checklists to aid measure selection [17,108]. 
There is also an argument, reflected by the findings of  
this review, for a multi-measurement approach, where 
multiple, complementary activity measures are employed, to 
improve the interpretation of physical activity measurement 
[14,15,16,80] and potentially improve measurement properties 
[104,107]. Recall bias can be neutralised by triangulation 
with real-time measurement and social desirability responding 
can be minimised by the knowledge that responses will be 
verified directly [109]. Recording both relative and absolute 
activity, by heartrate monitoring and accelerometry or 
GPS, can enrich physical activity data interpretation and 
has also been shown to improve measurement properties 
[110-113]. Thus, diaries, heartrate monitoring and, 
possibly, GPS might be suitable adjuncts to standardised 
questionnaires or accelerometry. A multi-measurement 
approach is recommended for the assessment of physical 
activity in adults with muscular dystrophy. 
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The current lack of research evaluating measurement 
properties of physical activity measurement in adults  
with muscular dystrophy means that authors should be 
encouraged to report study level reliability and validity of 
the measures employed in trials or observational studies. 
In addition, measure evaluation studies are required to 
determine the validity, reliability and responsiveness of 
physical activity measures for use with adults with 
muscular dystrophy. The evidence, both evaluative and 
incidental, compiled in this review was predominantly low 
quality-rated, often linked to sample sizes below the  
50-100 participant threshold set by COSMIN for high 
quality-ratings [27]. Sample size challenges include the 
rarity of adults with muscular dystrophy and restricting 
study designs to single diagnoses and/or separating 
ambulant and non-ambulant [1,17]. In larger samples, it is 
also difficult to find an activity measure suitable to 
encompass activity heterogeneity within and between 
muscular dystrophic diagnoses [114,115] and stages of 
disease progression [116,117,118]. Restrictive sampling is 
advocated for experimental designs [1]. However, to 
optimise statistical power, a larger, heterogeneous sample 
(with whole and sub-group analyses) is recommended for 
future evaluative studies where measurement properties 
are to be elucidated. 
For evaluative research, it is also difficult to identify a 
gold-standard criterion measure of physical activity. In the 
wider physical activity literature, criterion measures 
include calorimetry, accelerometry and direct observation 
[8,12,13,119]. Due to burden and cost, direct observation 
and indirect calorimetry are limited to smaller samples and 
short timeframes (<1 day). Calorimetry by double-labelled 
water is suitable over a timeframe of 1-2 weeks, but 
burdensome. Energy expenditure calculations should also 
be viewed with caution because calorimetry is likely to be 
impacted by metabolic abnormalities and progressive 
physiological changes in muscular dystrophy [18,19,90]. 
Whereas, direct observation has inherent content validity 
[119] and, in this review, it was interpretable and 
generalizable in 13 studies. Thus, it represents a suitable, 
initial gold-standard criterion for short-term validation. 
Accelerometry is generalizable in larger samples and over 
various timeframes. Thus, accelerometry, with prior 
validation against direct observation, might represent a 
suitable criterion against which to validate other activity 
measures for adults with muscular dystrophy. 
4.4. Strengths and Limitations 
To the authors’ knowledge, this is the first systematic 
review about measurement characteristics and properties 
of physical activity measures specifically for adults with 
muscular dystrophy. The review employed a broad, sensitive 
search strategy, 3 independent reviewers and rigorous 
COSMIN appraisal. However, there are some limitations. 
These include, firstly, exclusion of non-English language 
articles which means relevant articles published in other 
languages may have been missed. Nevertheless, a  
recent review of physical activity measures in adults and 
children with neuromuscular diseases [17] did not  
identify additional measurement approaches beyond those 
identified in this review; which suggests no pertinent 
measures were missed. Secondly, there is potential for 
bias in phase 1 as only a 10% sample was second reviewed 
and there was no methodological appraisal. However, the 
descriptive nature of phase 1 was straightforward, and the 
methodological quality of the studies did not impact 
description of the tool. Thirdly, COSMIN methodology 
was developed for patient-reported outcome measures, 
and as such, the participant number cut offs may be too 
stringent for direct measure evaluation where smaller 
participant numbers can be statistically robust [120]. 
Finally, risk of reporting bias was introduced by the 
inclusion of incidental hypothesis testing (indicative of 
discriminative or convergent relationships for which null 
findings are less frequently reported) thus the case for 
construct validity might have been artificially inflated. 
5. Conclusions 
Accelerometry, heartrate monitoring, direct observation, 
calorimetry, GPS, questionnaires and diaries have been 
used to assess physical activity in adults with muscular 
dystrophy. They were largely generalizable for adult age 
ranges, both genders and ambulant and non-ambulant people 
with a range of muscular dystrophy diagnoses. However, 
interpretability varied between measures and there was 
insufficient evidence to support their reliability, validity or 
responsiveness for use with adults who have muscular 
dystrophy. Measures identified as having most potential in 
this review included multi-axial accelerometry and the 
PASIPD questionnaire. Future evaluative studies of these, 
and/or other, physical activity measures for use with adults 
with muscular dystrophy are required. Future evaluative study 
design should consider direct observation as a fundamental 
criterion and maximizing sample size. Study design should 
include an awareness of activity measure limitations (in 
general and specific to muscular dystrophy) and the potential 
for improved interpretability by multi-measurement.  
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1. EXP Muscular Dystrophies 
2. Muscular dystrophy 
3. Facioscapulohumeral  
4. Limb girdle muscular dystrophy 
5. Becker’s muscular dystrophy 
6. Myotonic dystrophy 
7. Sarcoglycanopathy 
8. Duchene muscular dystrophy 
9. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 
10. Wheelchair 
11. 9 or 10 
12. Physical activity 
13. EXP human activities/ or "activities of daily living"/ or EXP social participation/ or EXP exercise/ or EXP circuit-
based exercise/ or EXP cool-down exercise/ or EXP muscle stretching exercises/ or EXP physical conditioning, human/ 
or EXP plyometric exercise/ or EXP resistance training/ or EXP running/ or EXP swimming/ or EXP walking/ or EXP 
warm-up exercise/ or leisure activities/ or recreation/ or dancing/ or gardening/ or EXP sports/ or EXP athletic 
performance/ or EXP physical endurance/ or EXP physical fitness/ or baseball/ or basketball/ or EXP bicycling/ or 
boxing/ or football/ or golf/ or gymnastics/ or hockey/ or martial arts/ or mountaineering/ or racquet sports/ or return to 
sport/ or running/ or jogging/ or skating/ or snow sports/ or soccer/ or EXP sports for persons with disabilities/ or 
swimming/ or "track and field"/ or volleyball/ or weight lifting/ or wrestling/ or youth sports/ 
14. EXP Motor Activity 
15. Energy expenditure 
16. Exercise 
17. Exercise movement techniques/ or breathing exercises/ or dance therapy/ or tai ji/ or yoga/ 
18. Exercise Test/ or Warm-Up Exercise/ or Cool-Down Exercise/ or Exercise Therapy/ or Plyometric Exercise/ or 
Circuit-Based Exercise/ or Exercise Tolerance/ or exp Exercise/ or Exercise Movement Techniques/ 
19. Aerobic 
20. Training 
21. 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 
22. Measures 
23. Self report 
24. Test 
25. Score 
26. Scale 
27. Ergometer 
28. Accelerometer 
29. Actometer 
30. Pedometer 
31. Treadmill 
32. Questionnaire 
33. Assess 
34. Index 
35. Level 
36. MET 
37. Week 
38. Frequency 
39. Intensity 
40. 22 or 23 or 24 or 25 or 26 or 27 or 28 or 29 or 30 or 31 or 32 or 33 or 34 or 35 or 36 or 37 or 38 or 39 
41. Evaluation.mp. or EXP evaluation study/ 
42. EXP methodology/ or EXP validation process/ or valid$.mp. 
43. Sensitivity. 
44. Specificity. 
45. Reliability 
46. EXP reliability/ or EXP observation/ or direct observation.mp. 
47. Responsiveness 
48. Validity 
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49. EXP outcome research/ or minimal clinically important difference.mp. 
50. 41 or 42 or 43 or 44 or 45 or 46 or 47 or 48 or 49 
51. 11 and 21 and 40 
51. 50 and 51 
52. EXP Health behaviour/ or EXP exercise/ or EXP Physical Activity/ or exercise behaviour.mp. 
53. Workload.mp. or EXP Workload/ 
54. EXP resistance training or resistance.mp. 
55. Effort.mp. or EXP exercise 
56. Speed.mp. or EXP velocity/ 
57. Heart rate.mp. or EXP heart rate/ 
58. Pulse rate/ or Pulse watch.mp. or heart rate/ 
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60. EXP accelerometer/ or Ankle step watch.mp 
61. EXP ambulatory monitoring/ or EXP Actimetry/ or EXP accelerometer/ or actigraph.mp. 
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63. Muscle metabolism/ or EXP oxygen consumption/ or metabolism/ or oxidative capacity.mp. 
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68. Daily life activity/ or activity log.mp. 
69. Training Diary.mp. 
70. Physical activity/ or physical performance/ or activity diary.mp. or questionnaire/ 
71. EXP resitance training/ or EXP exercise intensity/ or EXP exercise test/ or EXP bicycle ergometry/ or rating of 
perceived exertion.mp. or EXP rating scale/ 
72. Borg.mp. 
73. EXP rating scale/ or EXP visual analog scale/ or numerical rating scale.mp. 
74. Semi structured interview/ or structure interview/ or interview.mp. or telephone interview/ or unstructured interview/ 
or interview/ 
75. Frenchay Activities Index.mp. 
76. Checklist Individual Strength.mp. 
77. Sickness Impact Profile.mp. or Sickness Impact Profile/ 
78. Activity Card Sort.mp. 
79. Daily observation of activity.mp. 
80. Bouchard.mp. 
81. PASIPD.mp. or Physical Activity Scale for Individuals with Physical Disabilites.mp. 
82. IPAQ.mp. or EXP reproducibility/ or EXP physical activity/ or questionnaire/ or EXP validation study/ or EXP 
walking/ or self report/ 
83. International Physical Activity Questionnaire.mp. 
84. GLTEQ.mp. or Godin Leisure Time Exercise Questionnaire.mp. 
85. Oxidative capacity.mp. 
86. Physical self description questionnaire.mp. 
87. 52 or 53 or 54 or 55 or 56 or 57 or 58 or 59 or 60 or 61 or 62 or 63 or 64 or 65 or 66 or 67 or 68 or 69 or 70 or 71 or 
72 or 73 or 74 or 75 or 76 or 77 or 78 or 79 or 80 or 81 or 82 or 83 or 84 or 85 or 86 
88. 51 and 87 
89. Remove duplicates from 88. 
Appendix 2. Data extraction tool  
Phase 1/2 
  
Author(s) 
  
Title 
  
Year 
  
Study Design Pilot, feasibility, RCT, pre-post, measure evaluation, observational, cross sectional 
 
Study main purpose was study primarily aimed at testing an outcome measure of PA? Y/N 
 
Sample population 
being measured 
BMD, FSHD, LGMD, DM, DMD 
unspecified MD 
Rare (Myoshi, Bethlem, Laminin alpha, collagen 6, Emery-Dreifus etc)  
Sample size 
Number with MD 
Details of participants not diagnosed with MD  
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Aspect of physical 
activity (PA) 
measured 
Indirect (standardised questionnaires or diaries, non-standardised diaries, PA subsection, non-standardised questionnaire or 
interview, single scale PA level) 
Direct (accelerometry, heart rate monitoring, direct observation (including supervised exercise testing like VO2 and 
workload), positioning sensors (like GPS), calorimetry (double labelled water, indirect calorimetry) 
Interpretability (scope in terms of FITT framework) 
 
Measure(s) of PA 
Measurement tool(s) 
Exact wording from paper  
Measure 
administration 
Was the measure used to assess free-living PA? 
Is the administrative burden discussed (time frame, training, cognitive ability required by participant, cost, expertise, 
equipment, copyright, other) and was this burden considered acceptable?  
Tool development 
Concept to be measured stated (rationale and description, use of theoretical framework, intended population described, user 
involvement, item determination method appropriate)? 
Track back to referenced development paper  
Reliability 
Reliability (relative agreement) 
(i) test re-test:  ANOVA/t-test (or non-parametric equivalent) plus ICC, Kappa or Pearson's, Spearman's correlation 
coefficient, Bland and Altman relative agreement 
(ii) inter or intra-rater:  % agreement, ICC, Kappa or Kripendorff's alpha or other statistic? 
Measurement Error (absolute agreement) 
(i) test re-test:  ANOVA/t-test (or non-parametric equivalent), Kappa, Bland and Altman absolute agreement 
(ii) inter or intra-rater:  % agreement, Kappa or Kripendorff's alpha or other statistic? 
Internal consistency (for scale measures): Cronbach's alpha or other statistic (Kuder-Richardson formula 20, KR-20) 
Was the test robust? (interval between tests, adequate sample size, adequate results reported, reported by scale category if 
appropriate, appropriate statistics ICC or kappa ≥ 0.4, Kripendorff's alpha ≥ 0.8, alpha or KR-20 >0.7) 
 
Responsiveness 
What was the reported sensitivity to change or responsiveness? Cohen's d effect size, standardised response mean (SRM), 
Guyatt's. If scoring or cut-offs are part of data analysis, does the paper provide sufficient detail including information on 
response options, scoring cut offs and interpretation? 
Was this test robust? (interval between tests, change over time or change following intervention clearly reported, 
standardised response means, effect size, other statistic, adequate results reported) 
 
Validity 
Criterion Validity 
Concurrent validity (correlation with another measure of PA) What was the gold standard or other PA measure referenced? 
Statistics reported: ICC, regression, Pearson's, spearman's, t-test, % agreement or kappa, sensitivity/specificity table for 
dichotomous test 
Predictive validity (correlation with another measure of PA at a future time point) as above 
Construct Validity 
Hypothesis testing:   
Discriminative (extreme group difference), what where the different groups? ANOVA, T-test (or non-parametric equivalent 
e.g. Kruskal Wallace), mean (median) difference between groups. 
Convergent (correlation with a related construct to PA) what was the comparison measure? ICC, % agreement, regression, 
Pearson’s, spearman's, kappa, Bland and Altman 
Divergent (lack of correlation with unrelated construct to PA, sometimes referred to as discriminant - considered difficult to 
ascertain what might be unrelated in health research for such a broad construct as PA therefore not extracted) low correlation 
in above tests. 
Structural validity (for scale measures only): 
Internal validity, what was the result of the factor analysis (eigenvalue, coefficient, % total variance)?  
Cross cultural validity: 
What languages or settings are being compared (Bland and Altman, % agreement, Kappa) 
Content Validity: 
Were experts consulted or a formal content validity ratio/index established and what was it? Face validity assessed? Y/N 
Was this test robust? (adequate sample size, reported by scale category if appropriate, appropriate statistics ICC ≥ 0.4, r ≥ 
0.5, kappa ≥ 0.4 t-test p> 0.05, t > 1, adequate results reported) Was this internal validty test robust? (adequate sample size 5 
per item, reported by scale category if appropriate, appropriate statistics eigenvalue ≥ 1, factor loading high >0.6, low <0.4, 
coefficient ≥ 0.5, adequate results reported) 
 
COSMIN 
generalizability 
1. Median or mean age (with standard deviation or range) 
2. Distribution of sex (conservatively estimated by mean ±1 SD to account for potentially skewed lower age distributions, 
particularly in DMD) 
3. Important disease characteristics (e.g. severity, status, duration) and description of treatment 
4. Setting(s) in which the study was conducted (e.g. general population, primary care or hospital/rehabilitation care) 
5. Countries in which the study was conducted 
6. Language in which the HR-PRO instrument was evaluated 
7. Method used to select patients (e.g. convenience, consecutive, or random) 
8. Percentage of missing responses (response rate) 
 
COSMIN 
Interpretability 
1. Percentage of missing items 
2. Description of how missing items were handled 
3. Distribution of the total scores 
4. Percentage of participants with lowest possible score (floor effect) 
5. Percentage of participants with the highest possible score (ceiling effect) 
6. Scores and change scores (i.e. means and SD) for relevant (sub) groups, e.g. for normative 
groups, subgroups of patients, or the general population 
7. Minimal Important Change (MIC) or Minimal Important Difference (MID) 
Cohen's d effect size, standardised response mean (SRM), Guyatt's 
 
COSMIN checklist All relevant boxes A-I 
 
COSMIN score Excellent, good, fair or poor, Lowest score counts 
 
Comments 
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Table 3a. List of 63 measures used to assess adults with muscular dystrophy (27 indirect and 36 direct measures) 
Measure type 
(n) 
Measure Description of measurement (FITT parameters*) 
Timeframe 
(mode)  
Environment 
Metric  
(reported range) 
Participant 
mobility (n) 
Indirect 
standardised 
questionnaires 
and diaries (9) 
IPAQ  
(International 
Physical Activity 
Questionnaire)  
Collected activity time and frequency in minutes 
per day for types, including walking, transport, 
household, leisure and work, and intensity levels 
(moderate/vigorous) to yield overall estimated total 
energy expenditure [29,31,34-37]. (FITTO) 
7 days (recall) 
Free-living 
MET minutes 
per week (0-
15,918) 
 
Ambulant (462) 
Assisted (78) 
Wheelchair (125) 
N/R (417) 
PASIPD  
(Physical 
Activity Scale for 
Individuals with 
Physical 
Disabilities)  
Collected activity frequency and time in hours/days 
per week for 13 activity types, including work, 
exercise and household, each allocated intensity 
levels multiplied to yield an overall estimated 
energy expenditure score [32,39,42]. (FITTO) 
7 days (recall) 
Free-living 
MET hours per 
day (0-39.4†) 
 
Ambulant (20) 
Wheelchair (22) 
N/R (272) 
B-PAR  
(Bouchard 
Physical Activity 
Record)  
Recorded activity types (categorised by intensity 
levels 1-9) at a frequency of every 15 minutes over 
24 hours to yield an overall estimated total energy 
expenditure score [33]. (FITTO) 
3 days (real-
time) 
Free-living 
Kcal per day 
(1400-4400) 
N/R 
EPIC  
(EPIC-Norfolk 
Physical Activity 
Questionnaire)  
Collected time and frequency per week of listed 
activity types, including household, work and 
recreational categories, to yield hours per week for 
each activity and category [40]. (FTT)  
1 year (recall) 
Free-living 
Hours per week 
(0-8.4† hours 
recreational 
activity) 
Ambulant (11) 
PASE  
(Physical 
Activity Scale for 
the Elderly) 
Collected frequency and time (hours/days per 
week) for 13 activity types, including work, 
exercise and household, allocated intensity levels 
multiplied to yield an overall score [41]. (FITTO) 
7 days (recall) 
Free-living 
Arbitrary units 
(43-302) 
Ambulant (16) 
GLTEQ  
(Godin Leisure 
Time Exercise 
Questionnaire)  
Collected frequency of mild, moderate and 
strenuous activities lasting 15mins or more in 4 
questions, each intensity level allocated metabolic 
equivalents and multiplied to yield an overall 
exercise activity score [36]. (FITiO) 
7 days (recall) 
Free-living 
Arbitrary units 
(0-119) 
Ambulant (267) 
Wheelchair (54) 
CFS  
(The Canada 
Fitness Survey)  
Collected frequency, intensity and time for home, 
transport, work/school and leisure activity types, 
carried out yearly and seasonally, yielding an 
overall weighted activity score [43]. (FITTO) 
1 year (recall) 
Free-living 
Arbitrary units 
(2.3-21.7†) 
N/R 
BPAQ 
(Bone-specific 
Physical Activity 
Questionnaire)  
Collected types of activities carried out in each year 
of life, and frequency per week of activities carried 
out in the last year. Activities are rated according to 
bone-load and multiplied by time and frequency to 
produce the score [30,32]. (FTT) 
Lifetime / 1 
year (recall) 
Free-living 
Arbitrary units 
(0-4) 
Ambulant (29) 
Wheelchair (34) 
 
FAI  
(Frenchay 
Activities Index)  
Collected frequency of lifestyle activities, timing of 
work activities and intensity of household 
maintenance, each item rated 0-3 and summed to 
yield an overall score [38]. (FITTO) 
3-6 months 
(recall) 
Free-living 
Arbitrary units 
(19-32) 
N/R 
Indirect non-
standardised 
physical 
activity 
diaries (8) 
Electronic Diary 
(Activity entered 
into computer 
software)  
Recorded frequency, time and type of activity by 
location every 30 minutes throughout the day for 
triangulation with direct measure [47]. (FTT) 
1 day per week  
(real-time) 
Free-living 
Outdoor activity 
time per week 
(14.3 hours) 
Wheelchair (1) 
Activity Diary 
Recorded verification of direct measures non-wear 
time and non-wear activities [46,54-55] or all 
activities for clarification of true activity versus 
electrical interference or other events [40]. (FTT) 
3-7 days 
(real-time) 
Free-living 
Non-wear time 
(16-114† mins)  
Ambulant (32) 
Wheelchair (11) 
Bedridden (1) 
Activity Diary + 
DQ 
(Direct 
Quantifier: step 
count)  
Recorded daily walking activity by logging daily 
step counts in a diary [53]. (FITyO) 
6 months (real-
time) prescribed 
exercise at 
home 
Steps per day 
(estimated 
4500-6250) 
Ambulant (16) 
Log 
(training log)  
Collected training compliance by duration and 
frequency per week of training sessions, carried out 
on an exercise bike [29,33,49,51-52] or walking 
[48]. (FTT) 
8-14 weeks 
(recall) 
prescribed 
exercise at 
home/gym 
Sessions per 
week (0-4 x 15-
35 mins) 
Ambulant (54) 
Assisted (4) 
N/R (61) 
Log + Q 
(training log with 
self-report 
Quantifier: RPE)  
Recorded compliance by duration, frequency and 
type of activity (strength exercises and walking) 
with activity intensity quantified by Borg CR10 
rating of perceived exertion (RPE) [41]. (FITT) 
8 weeks (real-
time) prescribed 
exercise 
at home/gym 
Sessions per 
week (3.5 x 20 
mins); RPE 
(light to 
moderate) 
Ambulant (16) 
Log + DQ 
(training log with 
Direct 
Quantifier: HR/ 
rpm)  
Recorded compliance by duration and frequency of 
bike training sessions with intensity quantified by 
heartrate (HR) [50] and ergometer revolutions per 
minute (rpm) [45] recorded in log. (FITT) 
8 weeks (real-
time) prescribed 
exercise 
at home/gym 
Sessions per 
week (3-4† x 
30mins); rpm 
(60-90) 
Ambulant (6) 
N/R (9) 
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Measure type 
(n) Measure Description of measurement (FITT parameters*) 
Timeframe 
(mode)  
Environment 
Metric  
(reported range) 
Participant 
mobility (n) 
Indirect non-
standardised 
physical 
activity 
diaries (8) 
continued 
Log + Q/DQ 
(training log with 
mixed 
Quantifiers: RPE, 
HR and work)  
Recorded compliance by duration and frequency of 
walking/ bike training sessions with intensity 
quantified by RPE, heartrate (HR) (Uniq Pro 
Trainer [56]) and workload (Monark Ergometer) 
[44] and recorded in log. (FITT) 
12-16 weeks 
(real-time) 
prescribed 
exercise 
at home/gym 
Sessions per 
week (0-4x15-
31mins†); RPE 
(11.4-14.1†); 
Watts (43-99†) 
Ambulant (83) 
Telephone log + 
Q 
(training log with 
self-report 
Quantifiers: RPE 
and repetitions)  
Collected compliance by duration and frequency of 
strength exercises with intensity quantified by RPE 
(3-point scale 1 minimal, 2 moderate, 3 marked) 
and exercise resistance, sets and repetitions 
recorded in log [57]. (FITT) 
7 days (recall) 
prescribed 
exercise at 
home 
Sessions per 
week (2.5 x 15-
20mins); sets 
and reps (3 x 4-
8) 
Ambulant 
(estimated 10) 
Assisted 
(estimated 7) 
Indirect 
subscales of 
standardised 
questionnaires 
(4) 
PSDQ – activity 
(Physical Self-
Description 
Questionnaire)  
Assessed perception of physical activity 
participation by Likert rating (1 false to 6 true) of 
statements including examples of frequency, 
intensity, timing and type of activities, summed to 
yield an overall score [75]. (FITTO) 
Current 
perception 
Free-living 
N/R Wheelchair (4) 
ACS – 
participation 
ranking  
(Activity Card 
Sort)  
Ranks participation (frequency or duration) in a 
range of activity types (e.g. social and 
instrumental) and intensities (e.g. high and low 
physical demand) depicted on cards [58]. (FITT) 
N/R 
Free-living 
N/R N/R 
FPACQ – 
transport  
(Flemish 
Physical Activity 
Computerized 
Questionnaire)  
Collected duration and type/intensity of 
transportation (active (e.g. self-propelled wheeling) 
versus passive (e.g. motorised)) [72]. (ITT) 
7 days (recall) 
Free-living 
Minutes of 
transport per 
day (% active) 
(9-226† mins (< 
5%)) 
Wheelchair 
(estimated 30) 
MAQ – activity 
(Modifiable 
Activity 
Questionnaire)  
Collected frequency, duration and type of light and 
strenuous intensity exercise activities undertaken, 
including sports, competition and swimming [72]. 
(FITT) 
2 weeks (recall) 
Free-living 
Sessions per 
week (0->3 x 0-
64 mins) 
Wheelchair 
(estimated 42) 
Indirect 
single-rating 
activity scales 
(4) 
PAGS 
(Physical 
Activity Grading 
Scale)  
Collected overall activity rating, 1-6, for summer 
and winter (1-hardly any activity, 5- moderate 
exercise for 3hrs, 6 - hard exercise several times 
per week e.g. skiing, running) [38,48]. (FITTO) 
6-month 
seasons / 1 year 
(recall) 
Free-living 
Arbitrary rating 
(1-5) 
Ambulant (35) 
N/R (70) 
 
ACR 
(Activity Change 
Rating) 
Collected relative activity level rating from start to 
finish of intervention (worsened, unchanged or 
improved) [51-52]. (O) 
12-20 weeks 
(recall) 
Free-living 
worsened – 
improved 
N/R 
Activity 
Increment  
1-5 
Collected activity changes compared to baseline on 
a scale of 0 – no change to 3 – new activities 
undertaken [123]. (O) 
14 days (recall) 
Free-living 
N/R 
Ambulant (11) 
Wheelchair (2) 
DOA 
(Daily 
Observation of 
Activity)  
Recorded 4 times daily a rating of activity level 
from 0 (no activity) to 4 (extremely active) to yield 
an overall score out of 16, averaged over 14 days 
for each participant [65]. (O) 
14 days (real-
time) 
Free-living 
Arbitrary units 
(4.1-8.1†) 
Ambulant (65) 
Indirect non-
standardised 
questions and 
interviews (2) 
Interview 
(study specific) 
Collected frequency, time and type of exercise 
carried out in the year following an intervention 
[33], between clinic visits [124], hours of sporting 
activity (>/< 1000 hours) pre-onset [125] and 
prompted contextualisation of GPS tracker data 
[73]. (FTT)  
1 week-1 year/ 
pre-onset 
(recall) 
Free-living 
Sessions per 
week (2 x 25-30 
mins); n=7 > 
1000 hours pre-
onset 
Ambulant (16) 
Wheelchair (1) 
N/R (104) 
 
Survey 
(study specific)  
Collected physical activity level (PAL) on a single 
Likert scale from 0-10 and types of activity 
participated in at different times of life during 
school years and beyond) [122]. (ITT) 
Lifetime (recall) 
Free-living 
PAL (5-9†) N/R 
Direct 
accelerometric 
monitoring 
(10) 
Pedometer 
(Yamax 
Digiwalker, 
uniaxial 
pedometer)  
Recorded ambulatory activities, encompassing 
frequency, intensity and timing of stepping 
activities, expressed overall in steps per day and 
prescribed at 125% baseline [53]. (O) 
6 months (real-
time) prescribed 
exercise at 
home 
Steps per day 
(estimated 
4500-6250) 
Ambulant (16) 
Pedometer 
(unspecified)  
Recorded ambulatory activities, encompassing 
frequency, intensity and timing of stepping 
activities, expressed overall in steps per day [41]. 
(O) 
8 weeks (real-
time) prescribed 
exercise at 
home 
Steps per day 
(2798–8331) 
Ambulant (16) 
Pedometer 
(triaxial, Omron 
Walking Style 
Pro)  
Recorded ambulatory activities, encompassing 
frequency, intensity and timing of stepping 
activities, stride length used to calculate daily 
overall activity in cumulative distance [29]. (O) 
4-7 days (real-
time) 
Free-living 
Distance per 
day (1.0-4.2 
km) 
Ambulant (8) 
Assisted (4) 
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Measure type 
(n) 
Measure Description of measurement (FITT parameters*) 
Timeframe 
(mode)  
Environment 
Metric  
(reported range) 
Participant 
mobility (n) 
Direct 
accelerometric 
monitoring 
(10) continued 
Ankle actometer  
(unspecified)  
Records ankle movements overall (encompassing 
frequency, intensity and timing) [37]. (O) 
12 days (real-
time) 
Free-living 
N/R N/R 
Ankle Actometer 
(Actilog V3.0, 
triaxial 
accelerometer)  
Recorded ankle movements overall (encompassing 
frequency, intensity and timing) averaged as 
accelerations per 5-minute epoch [44,67,69]. (O) 
12 days (real-
time) 
Free-living 
Mean 
accelerations 
per 5 minutes 
(1-74) 
Ambulant (264) 
Ankle 
StepWatch™ 
(Step activity 
monitor (SAM) 
biaxial 
accelerometer)  
Recorded ankle movements overall averaged over 7 
days to yield mean steps per day, per minute within 
peak non-consecutive 30 minutes and highest 
sustained 20, 30 and 60 minutes and inactivity 
duration percentage total time [70-71]. (TiO)  
7 days and 
nights 
(real-time) 
Free-living 
Steps/day (716 
– 5412†) Peak 
steps per min 
(21-47†); 
Inactive (71-
90%) 
Ambulant (23) 
Wrist Actigraph 
(Motionlogger 
Watch, triaxial 
accelerometer)  
Recorded wrist movement counts overall 
(encompassing frequency, intensity and timing), 
analysed in terms of zero-crossing mode (ZCM) in 
counts per minute or proportional integration mode 
(PIM) in bits per second [46]. (O) 
7 days (real-
time) 
Free-living 
ZCM counts per 
min (5-220†); 
PIM bits per 
second (0-
90,000) 
Wheelchair (11) 
Bedridden (1) 
Actigraph 
(GTX3, triaxial 
accelerometer)  
Recorded steps overall (encompassing frequency, 
intensity and timing) [61]. (O) 
7 days (real-
time) 
Free-living 
N/R Ambulant (11) 
SenseWear Pro 
(temperature 
sensing biaxial 
accelerometer 
armband)  
Recorded arm movements and temperatures, 
algorithmically calculated as overall steps, and 
energy expenditure expressed as average 
kilocalories, per day [33]. (O) 
3 days (real-
time) 
Free-living 
Steps per day 
(2200-13400) 
Kcal per day 
(1800-3500) 
N/R 
Kinesense / Gene 
Active (triaxial 
accelerometers)  
Records movement counts overall (encompassing 
frequency, intensity and timing) [68]. (O) 
2 weeks (real-
time) 
Free-living 
N/R Ambulant (296) 
Direct 
heartrate 
monitoring (9) 
Garmin 
Pulsewatch 
(Forerunner 50)  
Recorded intensity of exercise in heartrate (HR) 
beats per minute (bpm) and downloads provided a 
record of frequency and duration of activity 
sessions [44]. (FITi) 
16 weeks (real-
time) prescribed 
exercise 
at home/gym 
HR (109-135† 
bpm); sessions 
per week (0-3 x 
29-31†mins) 
Ambulant (77) 
 
Polar Pulsewatch 
(RS400)  
Recorded intensity of exercise in heartrate (HR) 
beats per minute (bpm) and recorded timing and 
frequency of warm up/ work out sessions [59]. 
(FITi) 
6 months (real-
time) prescribed 
exercise at 
home 
HR (90-130 
bpm); sessions 
per week (2 x 
15-25mins) 
Wheelchair (1) 
Pulsewatch 
(make and model 
not specified)  
Recorded frequency, timing and intensity of 
heartrate (HR) training zone (linked to percentage 
maximal oxidative capacity (%VO2 max) 
(Cosmed, Quark CPET)34 or percent of predicated 
maximal heartrate (%HRM)59) [33,58]. (FITi) 
12-16 weeks 
(real-time) 
prescribed 
exercise 
at home/gym 
HR (50-70% 
HRM, 70% 
VO2max); 
sessions per 
week (1-3 x 15-
90 mins) 
N/R 
Polar Pulsewatch 
(model not 
specified)  
Recorded intensity of heartrate (HR) training zone 
(corresponding to percentage of maximal oxidative 
capacity (%VO2 max)(CPX MedGraphics)) and 
recorded timing and frequency of warm up/ work 
out sessions [51-52]. (FITi) 
32 mins - 12 
weeks (real-
time) prescribed 
exercise at 
home 
HR (65% 
VO2max) 
sessions per 
week (2-5 x 
35mins) 
N/R  
Polar Pulsewatch 
(S610)  
Recorded intensity of heartrate (HR) training zone 
(corresponding to percentage of measured or 
predicted maximal heartrate (HRM)) and 
downloads provided a record of frequency and 
duration of activity sessions [29,48]. (FITi) 
14-16 weeks 
(real-time) 
prescribed 
exercise 
at home/gym 
HR (60-87†% 
HRM); sessions 
per week (2-3 x 
20-44† mins) 
Ambulant (43) 
Assisted (4) 
Polar Pulsewatch 
(Accurex)  
Recorded intensity of heartrate (HR) training zone 
(corresponding to percentage of maximal oxidative 
capacity (%VO2 max) (CPE MedGraphics)) and 
downloads provided a record of frequency and 
duration of activity sessions [49-50]. (FITi) 
12 weeks (real-
time) prescribed 
exercise at 
home 
HR (65% 
VO2max) 
sessions per 
week (2-5 x 
30mins) 
Ambulant (11) 
N/R (9) 
Polar Pulsewatch 
(FT40)  
Recorded intensity of heartrate (HR) training zone 
(corresponding to percentage of maximal oxidative 
capacity (%VO2 max)) and downloads provided a 
record of frequency and duration of activity 
sessions [45]. (FITi) 
10 weeks (real-
time) prescribed 
exercise at 
home 
HR (70% 
VO2max) 
Sessions per 
week (3-4 x 10-
30mins) 
Ambulant (6) 
Polar Pulsewatch 
(Vantage XL)  
Recorded continuous heartrate, analysed by time, 
frequency and overall activity above flex heartrate 
(HR) (established individually from rest and low 
speed treadmill walking test heartrate + 10 beats 
per minute) [53-55]. (FITiO) 
3 days (real-
time) 
Free-living 
Active minutes 
per day (29-
232†mins) 
Ambulant (37) 
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Measure type 
(n) 
Measure Description of measurement (FITT parameters*) 
Timeframe 
(mode)  
Environment 
Metric  
(reported range) 
Participant 
mobility (n) 
Direct 
heartrate 
monitoring (9) 
continued 
Polar heart 
monitor 
(model not 
specified)  
Recorded continuous heartrate, analysed by time, 
frequency and overall activity above flex heartrate 
(HR) (established individually from rest and 
treadmill walking tests; flex HR = 87-102† bpm) 
and percentage maximal heartrate (HRM) [40]. 
(FITiO) 
3 days (real-
time) 
Free-living 
Active per day 
(8-251mins); at 
40% and 70% 
HRM (8-24mins 
and 1min) 
Ambulant (11) 
Direct 
observation 
(7) 
Step counting 
Observed type (walking) with frequency and 
intensity indicated by number of steps counted 
within timeframe [61]. (FITT) 
7 days (real-
time) 
Laboratory 
testing 
N/R Ambulant (11) 
Supervision  
(Supervised 
exercise)  
Observed frequency, duration and type of exercise 
(tailored [58], strength [65] or ergometer cycling 
[51]) carried out in the gym or during home visits, 
with intensity of cycling rated vicariously as easy, 
hard or maximal [29] or resistance [65]. (FITT) 
8-52 weeks 
(real-time) 
prescribed 
exercise at 
home 
Cycling 
intensity (easy-
maximal) 
Sessions per 
week (3-4† x21-
34mins) 
Ambulant (8) 
Assisted (4) 
N/R (estimated 
25) 
Supervision + Q 
(Supervised 
exercise with 
Quantifier: RPE)  
Observed frequency, duration and type of class 
exercises (warm up, flexibility, strength, balance, 
aerobic and cool down exercises), with participant-
rated intensity between 1 (much too easy), 3 
(sufficient) and 5 (far too strenuous) [48]. (FITT) 
14 weeks (real-
time) prescribed 
exercise at gym 
Exercise class 
intensity (3-4); 
sessions per 
week (2 x 
60mins) 
Ambulant (35) 
 
Supervision + 
DQ 
(Supervised 
exercise with 
Direct 
Quantifier: 
heartrate (HR))  
Observed frequency, duration and type of exercise 
(treadmill walking and ergometer cycling) with 
intensity quantified by ECG HR monitoring (and 
brachial pulse palpation [74] (corresponding to % 
HRM [66] and %VO2 max [74]). (FITT) 
12 weeks – 6 
months (real-
time) prescribed 
exercise at 
home/gym 
Walking/cycling 
HR (70% 
VO2max / 70-
85% HRM); 
sessions per 
week (4 x 15-
30mins) 
N/R 
Supervision + 
Q/DQ 
(Supervised 
exercise with 
mixed 
quantifiers: RPE, 
work, HR)  
Observed frequency, duration and type of exercise 
(cycle ergometer pedalling) with intensity 
quantified by rating or perceived exertion (RPE), 
ergometer workload and heartrate (HR) (linked to 
percentage maximal oxidative capacity (%VO2 
max) or maximal HR) [44,62-64]. (FITT) 
40-42 mins – 16 
weeks (real-
time) prescribed 
exercise at 
home/ 
laboratory 
RPE (11-17†); 
Watts (43-
109†); HR (95-
177† bpm) 
sessions per 
week (0-3 x 20-
42mins) 
Ambulant (106) 
Wheelchair (2) 
N/R (4) 
Video + DQ 
(Supervision via 
Skype with Direct 
Quantifier: 
workload)  
Observed frequency, duration and type of exercise 
(arm cycling and strength exercises), with intensity 
quantified by ergometer workload in Kilocalories 
per minute and Theraband 50% lengthening [59]. 
(FITT)  
8 weeks (real-
time) prescribed 
exercise at 
home 
Work in Kcal 
per minute (4); 
sessions per 
week (4 x 15-
30mins) 
Ambulant (65) 
Wheelchair (1) 
Spectating + Q 
(Observation of 
competitive sport 
with Quantifier: 
RPE)  
Observed frequency, duration and type of 
continuous wheelchair soccer play during 
scrimmages and game halves with intensity 
measured by rating of perceived exertion (RPE) 
Borg 6-20 [60]. (FITT) 
2 days (real-
time) 
competitive 
sport pitch 
Wheelchair 
soccer RPE 
(9.6-16.7†) 
active game 
time (10-15min) 
Wheelchair (4) 
Direct energy 
expenditure 
measurement 
(8) 
Indirect 
calorimetry 
(by gas analyser 
(K4b2))  
Recorded frequency and time during training and 
match play spent at different intensities quantified 
by oxidative capacity (VO2) in metabolic 
equivalents (METs) measured using a telemetric 
portable gas analyser [60]. (FITi) 
10-15mins (real 
time) 
competitive 
sport pitch 
VO2 in METs 
(0.98-2.54†) 
Wheelchair (4) 
Indirect 
calorimetry 
(by gas analyser 
(Oxycon 
Mobile))  
Recorded frequency and time during training and 
match play spent at different intensities quantified 
by oxidative capacity (VO2) in metabolic 
equivalents (METs) measured using a telemetric 
portable gas analyser [60]. (FITi) 
10-15mins (real 
time) 
competitive 
sport pitch 
VO2 in METs 
(0.98-2.54†) 
Wheelchair (4) 
Indirect 
calorimetry 
(by gas analyser 
(Quark b2, 
Cosmed))  
Recorded frequency and time during ergometer 
interval cycling spent at different intensities 
quantified by oxidative capacity (VO2) in 
millilitres of oxygen per minute per kilogram of 
body weight, measured using an online gas 
analyser [64]. (FITi) 
20mins (real-
time) 
Laboratory 
testing 
VO2 in 
ml/min/kg  
(11-37†) 
Ambulant (12)  
Wheelchair (2) 
Indirect 
calorimetry 
(by gas analyser 
(2900 Metabolic 
System))  
Recorded frequency and time during treadmill 
walking at 3 speeds, for each reaching 5 minutes of 
steady state intensity quantified by oxidative capacity 
(VO2) in millilitres of oxygen per minute, measured 
using an online gas analyser [53-55]. (FITi) 
15+mins (real-
time) 
Laboratory 
testing  
VO2 in ml/min 
(579-1109†) 
Ambulant (37) 
TEE by DLW 
(Total Energy 
Expenditure by 
Double -Labelled 
Water)  
Recorded overall energy in Kilocalories per day 
calculated by double-labelled water technique 
monitoring excretion of stable isotopes (2H2O and 
H218O) [127]. (O) 
N/R (real-time) 
Free-living 
Energy in Kcal 
per day (948-
1320) 
N/R 
 
 Journal of Physical Activity Research 21 
Measure type 
(n) 
Measure Description of measurement (FITT parameters*) 
Timeframe 
(mode)  
Environment 
Metric  
(reported range) 
Participant 
mobility (n) 
Direct energy 
expenditure 
measurement 
(8) continued 
TEE by dietary 
intake 
(Total Energy 
Expenditure by 
dietary intake)  
Recorded overall energy in Kilocalories per day 
calculated by average daily dietary intake in 
participants who maintained a stable weight over 
6 months preceding the measurement period 
[126-127]. (O) 
3 days (real-
time) 
Free-living 
and hospital-
living 
Energy in Kcal 
per day (1,033-
1600†) 
Wheelchair (6) 
N/R (26) 
TEE by 
HR/VO2/Diary 
(Total Energy 
Expenditure by 
diary/ HR/VO2)  
Recorded in Kilojoules per day by heartrate (HR) 
monitoring data calculated into energy 
expenditure by individually established treadmill 
oxidative capacity (VO2) equivalence and 
factorial diary calculations for gaps in heartrate 
data [53-55]. (O) 
3 days (real 
time) 
Free-living 
Energy in KJ per 
day (6340-
13,820†)  
 
Ambulant (37) 
PAL (TEE/REE) 
(Physical 
Activity Level 
index) 
Extrapolated as an index calculated from total 
energy expenditure (TEE) divided by resting 
energy expenditure (REE) measured by indirect 
calorimetry [53-54,126-127]. (O) 
3 days (real 
time) 
Free-living 
and hospital-
living 
PAL index (0.45-
2.03†) 
Ambulant (24) 
Wheelchair (6) 
N/R (26) 
Direct 
positioning 
systems (2) 
UbiTrak 
(GPS/Wi-Fi) 
(Global 
Positioning 
System and 
Wireless Fidelity 
system)  
Recorded frequency, time and type (by location) 
of indoor and outdoor movements by wheelchair 
tracking system linked to Wi-Fi and GPS, 
augmented by an electronic activity diary, 
intensity quantified by distance travelled [47]. 
(FTT) 
1 day per 
week  
(real-time) 
Free-living 
Hours outdoors 
(14.3); Miles 
travelled outdoors 
(42.5)  
Wheelchair (1) 
PAMS (GPS) 
(Participation 
and Activity 
Measurement 
System)  
Recorded frequency, time and type (by location) 
of community activities (work, social, daily 
living and recreational) by Global Positioning 
System (GPS) wheelchair tracking [73]. (FTT) 
14 days (real-
time) 
Free-living 
Metres wheeled 
(319-3795m) 
Wheelchair (1) 
† Range calculated by mean (or median) ± 1 standard deviation (or confidence interval) in the absence of reported range. Abbreviations: * FITT: F – 
frequency; I – intensity; Ti/T – time; Ty/T – Type of physical activity; O – overall physical activity; Q – Quantifier (by additional indirect measure); D 
– Direct quantifier (by additional direct measure); VO2 – oxidative capacity; HR – Heartrate; HRM – maximal heartrate; ZCM – zero crossing mode; 
PIM – proportional integration mode; RPE – rating of perceived exertion; ECG – Electrocardiogram; MET – metabolic equivalent; TEE – total energy 
expenditure; DLW – double-labelled water; PAL – Physical activity level index; REE – resting energy expenditure; GPS – Global positioning system, 
N/R – not reported. 
Table 4a. Study characteristics of studies and evaluated measures included in phase 2 
Author Study Description Measure(s) Measurement properties 
COSMIN 
rating 
Rosenberg et 
al., 2013 
 
Observational descriptive 
cross-sectional study 
testing associations 
between depression and 
physical activity in 1676 
people with NMD [36] 
1. IPAQ  
(International Physical 
Activity Questionnaire) 
2. GLTEQ  
(Godin Leisure Time 
Exercise Questionnaire) 
Incidental Construct validity 
1. and 2. Incidental convergent validity was demonstrated 
for both questionnaires by moderate negative associations 
with depression (Patient Health Questionnaire-9) 
(multiple linear regression, IPAQ Beta=-0.06, r2=0.004, 
P=0.012 and GLTEQ Beta=-0.13, r2=0.02, p<0.001) 
 
GOOD 
 
Jacques et 
al., 2017 
 
Observational analytic 
cross-sectional study of 
resting energy expenditure 
and comparison to healthy 
controls [30] 
 BPAQ  
(Bone-specific Physical 
Activity Questionnaire) 
Incidental Construct validity 
Incidental discriminative validity was demonstrated by 
extreme group differences in BPAQ score (current) 
between healthy controls and adults with BMD 
(Independent student t-test, p<0.05, mean difference in 
score 4.8) and between control, ambulatory and non-
ambulatory adults with BMD (ANOVA, P<0.01, mean 
difference in score 1.4) 
 
FAIR 
Heutinck et 
al., 2017 
 
Observational analytic 
cross-sectional study of 
physical activity and 
comparison to healthy 
controls [72] 
1. FPACQ - transportation 
(Subscale of Flemish 
Physical Activity 
Computerized 
Questionnaire)  
2. MAQ - activity 
(Subscale of Modifiable 
Activity Questionnaire) 
Incidental Construct validity 
1. Incidental discriminative validity was demonstrated by 
extreme group differences in FPACQ transportation time 
and type (active/passive) between healthy controls and 
people with DMD (independent t-test, p<0.001, mean 
difference 51 minutes less for healthy controls) at early 
and late non-ambulatory stages (independent t-test, 
p<0.003, mean differences 48 and 84 minutes respectively 
less for healthy controls). In addition, extreme group 
differences between early ambulatory stage and late 
ambulatory stage for people with DMD (One-way 
ANOVA with post hoc tests, p<0.022, mean difference 84 
minutes). 
2. Incidental discriminative validity was demonstrated by 
extreme group differences in MAQ light and strenuous 
activities by people with DMD at various stages of 
disease progression from early ambulatory to late non-
ambulatory (One-way ANOVA with post hoc tests, 
p<0.01, mean difference 29% and 34% more doing no 
light and strenuous exercise respectively) 
 
FAIR 
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Author Study Description Measure(s) Measurement properties 
COSMIN 
rating 
Janssen et al., 
2016 
Randomised, controlled 
trial secondary analysis for 
measure evaluation of MRI 
fat fraction analysis [67] 
Ankle Actometer 
(Actilog V3.0, triaxial) 
Incidental Construct validity 
Incidental convergent validity of ankle actometer (in 
average accelerations per 5 minutes over 12 days) with 
Magnetic Resonance Imaging (MRI) fat fraction of thigh 
musculature was demonstrated by a moderate negative 
correlation (Pearson’s r2=0.27, p=0.0013) 
 
FAIR 
 
Morse et al., 
2016 
 
Observational analytic 
cohort study of bone health 
in different muscular 
dystrophies and 
comparison to healthy 
controls [32] 
1. BPAQ  
(Bone-specific Physical 
Activity Questionnaire) 
2. PASIPD  
(Physical Activity Scale 
for Individuals with 
Physical Disabilities) 
Incidental Criterion validity 
1. and 2. Incidental concurrent validity was demonstrated 
between BPAQ and PASIPD by a strong association 
(reported in a later study31) between the 2 questionnaires 
(Pearson’s, r=0.71, p<0.005) 
Incidental Construct validity 
1. Incidental discriminative validity was demonstrated by 
extreme group differences in BPAQ score between 
healthy controls and adults with muscular dystrophy (one-
way between groups ANOVA with Bonferroni post hoc, 
p<0.05, mean difference in score 21) and between DMD 
and all other groups (one-way between groups ANOVA 
with Bonferroni post hoc, p<0.05, mean difference in 
score 24) 
1. Incidental convergent validity was demonstrated by low 
associations of BPAQ scores with bone ultrasound scores 
from the radius and tibia (Pearson’s, r=0.41-0.42, p<0.01 
and r=0.39, p<0.05 respectively). 
2. Incidental discriminative validity was demonstrated by 
extreme group differences in PASIPD score between 
DMD and all other muscular dystrophies (LGMD, FSHD 
and BMD) (Kruskal Wallis test, with post-hoc Mann-
Whitney U pairwise comparisons, p<0.05, mean 
difference in score 13) 
2. Incidental convergent validity was demonstrated by low 
and moderate associations of PASIPD scores with tibialis 
anterior cross-sectional area and grip strength (Pearson’s, 
r=0.46, p<0.01 and r=0.65, p<0.05 respectively). 
 
FAIR 
Smith et al, 
2016 
 
Observational analytic 
cohort study of the 
incidence, prevalence, age 
of onset and predictors of 5 
chronic conditions in 1594 
adults with long-term 
physical disability [31] 
IPAQ  
(International Physical 
Activity Questionnaire) 
Incidental Construct validity 
Discriminative validity was not demonstrated as there was 
no significant difference between IPAQ scores for 
participants with and without new onset of any chronic 
comorbid condition over the 3.5-year time period 
(independent student t-test, t = -0.85 to 1.69, df=1173, 
p>0.05, IPAQ mean score differences for hypertension = 
188.3, coronary heart disease = 372.6, cancer = 26.2, 
diabetes = 206.8 and arthritis = 0.0).  
 
FAIR 
Voet et al., 
2014 
 
Randomised controlled, 
crossover trial of aerobic 
exercise training and 
cognitive-behavioural 
therapy on chronic fatigue 
[44] 
Ankle actometer 
(Actilog V3.0, triaxial) 
Incidental Construct validity 
Incidental discriminative validity was demonstrated by 
extreme group differences in average accelerations per 5 
minutes between participants receiving Aerobic Exercise 
Training (AET), or Cognitive Behavioural Therapy 
(CBT), and those who received usual care (linear mixed 
model for repeated measurements, p<0.05, mean 
differences AET 4.6, CBT 5.6 and at follow up AET 5.5, 
CBT 7.1) 
 
FAIR 
Kierkegaard 
et al., 2011b 
 
Pilot randomised 
controlled trial of Friskis & 
Svettis Open doors 
exercise classes in 35 
adults with Myotonic 
Dystrophy [48] 
1. Training log 
2. Direct observation of 
exercise classes 
3. Polar Pulsewatch 
Incidental Construct validity 
1., 2. and 3. Incidental convergent validity was 
demonstrated for all 3 measures used as a composite to 
assess adherence, by good correlation with exercise self-
efficacy scores (Spearman’s r=0.75, p<0.001) 
 
FAIR 
Phillips et al., 
2009 
Observational descriptive 
cross-sectional study of 
activity patterns and 
barriers in 13 people with 
NMD and comparison to 
healthy controls [40] 
1. Polar heartrate monitor 
(Polar Electro UK ltd) 
2. EPIC 
(Norfolk Physical Activity 
Questionnaire) 
Incidental Construct validity 
1. Incidental discriminative validity was demonstrated by 
extreme group differences in minutes active (above flex 
heartrate) between people with NMD and healthy controls 
on 3 week and weekend days (Mann Whitney U test, 
p<0.05, median difference 154 minutes active) 
2. Incidental discriminative validity was demonstrated by 
extreme group differences between people with NMD and 
healthy controls in hours per week spent in overall 
physical activity measured by EPIC (Mann Whitney U 
test, p<0.004, mean difference 24.1 hours per week) and 
work-related activities (Mann Whitney U test, p<0.002, 
median difference 21.5 hours/week). There was a 
significant difference in choice of mode of transport to 
travel 1 mile (Fisher's exact test, p<0.02, frequency 
difference 10 more control participants chose walking). 
There was no significant difference in household activities 
or recreational hours per week between groups. 
FAIR 
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Author Study Description Measure(s) Measurement properties 
COSMIN 
rating 
Kalkman et 
al., 2007 
Observational analytic 
case-control study of 
predictors of fatigue in 198 
people with NMD [69] 
Ankle Actometer  
(Actilog, V3.0, triaxial) 
Incidental Construct validity 
Incidental convergent validity of average accelerations per 
5 minutes from 12 days was demonstrated by low 
negative correlation with Sickness Impact Profile 
(Pearson’s r = -0.38, p<0.01, FSHD and r= -0.38, p<0.01, 
Dystonia Myotonica) and Checklist Individual Strength – 
fatigue (Pearson’s r= -0.34, p<0.01, FSHD) 
 
FAIR 
 
Longmuir et 
al., 2000 
Observational descriptive 
cross-sectional study of 
habitual physical activity, 
perceived fitness and 
participation in 987 
disabled youths [43] 
CFS  
(Modified Canada Fitness 
Survey) 
Reliability 
Test-re-test reliability of the CFS ranged from 0.66 to 
1.00 (reported from an earlier study [76]) 
Incidental Construct validity 
Incidental discriminative validity was demonstrated by 
significant extreme group differences in activity level 
measured by the CFS between participants with physical 
disabilities (including MD) and those with hearing 
impairments or chronic illness (such as congenital heart 
defects, Cystic Fibrosis, Arthritis, kidney disease) (ANOVA, 
p=0.001, mean difference 8.1 points on CFS, Chi Squared, 
p=0.001, difference of 24% fewer active) and between 
those with MD versus head injury and Spina Bifida 
(ANOVA, p=0.001, mean difference 10.05 points on CFS, 
Chi squared, p=0.001, difference of 31.5% fewer active). 
 
FAIR 
McCrory et 
al., 1998 
 
Observational analytic 
cross-sectional study of 
energy expenditure and 
physical activity patterns in 
26 ambulatory adults with 
slowly progressive NMD 
and comparison to healthy 
controls [55] 
1. Diary 
(3-day activity and  
non-wear log book or 
Dictaphone logging with 
energy expenditure by 
factorial method) 
2. TEE and PAL 
(established by indirect 
calorimetry (2900 
Metabolic System) with 
heartrate equivalence  
3. Polar XL vantage 
Incidental Construct validity 
1., 2. and 3. Incidental discriminative validity was 
demonstrated by extreme group differences in TEE 
(derived from factorial diary, calorimetry and heartrate 
monitoring) between healthy controls and adults with 
NMD, and between genders (2 factor multivariate 
ANCOVA, respectively p=0.001 and p=0.007, mean 
differences = 2.61MJ/day and 2.44MJ/day). Similarly, for 
ACTEE and ACTEE as a percentage of TEE (2 factor 
univariate and multivariate ANCOVA, p≤0.001 and p=0.05, 
mean differences = 2.19MJ/day and 1.64MJ/day and 
p≤0.001 and p<0.0001, mean differences = 15% and 9%). 
1. Incidental discriminative validity was demonstrated by 
extreme group differences between genders and compared 
to healthy controls in diary reported exercise duration, 
energy expenditure and intensity (light versus moderate) 
between healthy controls and NMD (2 factor multivariate 
ANCOVA, p<0.02, p≤0.03, mean differences: 20mins, 
0.5 MJ/day and 2.0 PAL and 55 mins, 1.26 MJ/day and 
1.3 PAL respectively) 
2. and 3. Incidental convergent validity was demonstrated 
by a significant relationship between TEE and active 
minutes and adiposity (multiple regression analysis, 
R2=0.63 for a regression model including age, gender, 
TEE, minutes active and free fat mass, Partial R = -0.49 
for active minutes, p≤0.0001 and p=0.002) 
3. Incidental discriminative validity was demonstrated by 
extreme group differences in active minutes and heartrate 
between genders and between healthy controls and NMD 
(2 factor multivariate ANCOVA, respectively p=0.001 
and p=0.002, mean difference = 132 min/day and 
122min/day less, 11-12bpm). 
 
FAIR 
Andersen et 
al., 2017 
 
Randomised, controlled, 
crossover trial comparing 8 
weeks of high intensity 
interval training with usual 
care and comparison to 
healthy controls [29] 
1. IPAQ  
(International Physical 
Activity Questionnaire) 
Accelerometer:  
2. Pedometer  
(Omron Walking Style Pro 
Pedometer HJ-720IT-E2) 
Incidental Construct validity 
1. Incidental discriminative validity was demonstrated by 
extreme group differences in IPAQ (MET hours per 
week) between people with FSHD 1 and healthy controls 
(equal variance test and 2 tailed t-test or Mann–Whitney 
rank-sum test, p<0.05, mean difference in score 13) 
2. Incidental discriminative validity was demonstrated by 
extreme group differences in Omron step distance (km per 
day) between people with FSHD 1 and healthy controls 
(equal variance test and 2 tailed t-test or Mann–Whitney 
rank-sum test, p<0.05, mean difference in score 2.4) 
 
POOR 
Barfield et 
al., 2016 
 
Observational descriptive 
cross-sectional study of 
exercise intensity during 
power wheelchair soccer in 
30 people with mobility 
impairments [60] 
1. Indirect calorimetry 
(portable gas analyser: K4 
b2c) 
2. Indirect calorimetry 
(Oxycon Mobiled) 
Incidental Reliability 
1. and 2. Incidental inter-rater reliability was 
demonstrated by no significant difference in METS 
between gas analysers (K4 b2c versus Oxycon Mobiled) 
(independent group t-tests, p>0.05)  
Incidental Construct validity 
1. and 2. Incidental discriminative validity was 
demonstrated by extreme group difference in METS 
between rest and game play exertion (repeated measures t-
test, p<0.01, mean difference = 0.46METS) 
 
POOR 
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Author Study Description Measure(s) Measurement properties 
COSMIN 
rating 
Andersen et 
al., 2013 
Observational analytic 
cohort study of response to 
high intensity aerobic 
exercise and comparison to 
sedentary controls [64] 
1. Indirect calorimetry 
(Online gas analyser: 
Quark b2; Cosmed) 
2. Direct observation of
training with Heartrate 
monitoring via exercise 
bike telemetry (Monark 
939E) and Borg RPE  
Incidental Construct validity 
1. and 2. Incidental discriminative validity was
demonstrated by extreme group differences in activity 
intensity during continuous (65% and 75% maximal 
oxidative capacity (VO2max)) or interval (85% and 95% 
VO2max) cycling, measured by: 
Indirect calorimetry (mean VO2 ml/min/kg): significant 
differences between healthy controls and people with 
LGMD and BMD (unpaired student t-test), p<0.05, mean 
differences = 11-16 and 14-18 respectively). There was no 
significant difference between FSHD and healthy controls. 
Heartrate (bpm), for which there were significant 
differences between people with LGMD and healthy 
controls (unpaired student t-test, p<0.05, mean differences 
= 29-38). There were no significant differences between 
healthy controls and people with BMD and FSHD. 
POOR 
Kierkegaard 
et al., 2011a 
Observational descriptive 
cross-sectional study of 
functioning and disability 
[38] 
1. FAI 
(Frenchay Activities Index) 
2. PAGS
(Physical Activity Grading 
Scale) 
Incidental Construct validity 
1. Incidental discriminative validity was demonstrated by 
extreme group differences in FAI score between 
participants with mild and severe impairment  
(Mann-Whitney U test, p<0.001, mean difference = 9) 
2. Incidental discriminative validity was demonstrated by 
extreme group differences in PAGS rating between 
participants with mild and severe impairment (Mann-
Whitney U test, p=0.001, mean difference N/R) 
POOR 
Van der Kooi 
et al., 2007 
Randomised controlled, 
crossover trial 
investigating the effect of 
strength training and 
albuteral on pain and 
fatigue [65] 
DOA 
(Daily Observation of 
Activity) 
Incidental Construct validity 
Incidental discriminative validity was not demonstrated, 
there were no extreme group differences in DOA score 
between participants who reported pain/severe fatigue and 
those who did not (t-test, p=0.3 and p=0.33) 
Incidental convergent validity was not demonstrated there 
was no correlation between DOA score and pain/fatigue 
measured using Daily Observation of Pain/Fatigue 
(Pearson’s, r=0.06, p=0.66 and r = -0.05, p = 0.73 
respectively). 
POOR 
Wiles et al., 
2006 
Observational analytic 
cohort study of falls and 
associated risk factors and 
comparison to healthy 
controls [70] 
StepWatch™  
(Ankle step activity 
monitor (SAM, biaxial, 
Cymatech, USA) 
Incidental Construct validity 
Incidental discriminative validity was demonstrated by 
extreme group differences between healthy people and 
people with DM (mean differences: daily step count = 
2876, p<0.001, peak 30-min step rate = 19.8, p<0.001, 
sustained 60-min step rate = 11.8, p=0.002, time inactive 
= 8.4%, p=0.01) 
Incidental convergent validity was not demonstrated for 
mean daily step count over 7 days with strength 
(Spearman’s rank correlation not significant, r=0.6, 
p>0.06). 
POOR 
Dawes et al., 
2006 
A pilot randomised, 
controlled trial of a home-
based exercise programme 
in 20 adults with NMD 
[41] 
1. PASE
(Physical Activity Scale 
for the Elderly) 
2. Pedometer 
(unspecified) 
Incidental Responsiveness 
1 and 2. Incidental specificity of PASE and pedometer 
counts was demonstrated by no significant changes in 
either activity measure after the intervention (Wilcoxon, 
p>0.05, mean difference PASE = -11.64 (SD 38.31) and 
step count = -1485 (SD 2681) 
POOR 
Aitkens et 
al., 2005 
Observational analytic 
cohort study of risk factors 
for cardiovascular disease 
and diabetes in 11 
ambulatory adults with 
NMD and comparison to 
healthy controls [54] 
1. Diary 
(3-day activity and non-
wear log book or 
Dictaphone logging with 
energy expenditure by 
factorial method) 
2. TEE and PAL 
(established by indirect 
calorimetry (2900 
Metabolic System) with 
heartrate equivalence  
3. Polar XL vantage 
Incidental Construct validity 
1. Incidental discriminative validity was demonstrated by 
extreme group differences in self-reported activity 
minutes of exercise between healthy controls and adults 
with NMD at baseline and follow up (Repeated measures 
ANOVA, p=0.05, mean difference = 34mins/day at 
baseline and 20mins/day at follow up) 
2. and 3. Incidental discriminative validity was
demonstrated by extreme group differences in indirect 
calorimetry derived PAL between healthy controls and 
adults with NMD at baseline and follow up (Repeated 
measures ANOVA, p≤0.027, mean difference = 0.5 at 
baseline and 0.3 at follow up). Incidental discriminative 
validity was not significant extreme group differences for 
TEE alone (p>0.05). 
3. Incidental discriminative validity was demonstrated by 
extreme group differences in heartrate derived active 
minutes between healthy controls and adults with NMD at 
baseline and follow up (Repeated measures ANOVA, 
p=0.037, mean difference (less for adults with NMD) = 
70mins/day at baseline and 160mins/day at follow up) 
POOR 
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Author Study Description Measure(s) Measurement properties 
COSMIN 
rating 
Kilmer et al., 
2005 
Observational analytic 
cohort study testing the 
efficacy of a home-based 
activity and diet 
intervention in 20 people 
with slowly progressive 
NMD [53] 
1. TEE and PAL 
(established by HR 
equivalence with indirect 
calorimetry (2900 
Metabolic System) 
2. HR (Polar XL vantage)
3.Pedometer 
(Yamax Digi-Walker) 
Incidental Construct validity 
1. and 2. Incidental discriminative validity was not
demonstrated by extreme group differences in TEE and 
PAL pre and 6 months post intervention (1 way repeated-
measures ANOVA, p>0.05). 
3. Incidental discriminative validity was demonstrated by 
extreme group differences in pedometer daily step count 
pre and post intervention (1 way repeated-measures 
ANOVA, p=0.001, mean difference 1,250 steps/day). 
3. Incidental convergent validity was not demonstrated for
pedometer daily step counts, there was no correlation with 
fitness measured (submaximal heartrate and VO2 testing) 
at 3 walking speeds (Pearson's correlation, p>0.05) 
POOR 
Abbreviations: ICC – intraclass correlation coefficient, NMD – neuromuscular diseases; DMD – Duchenne’s Muscular Dystrophy; FSHD – 
Facioscapulohumeral Dystrophy; LGMD – limb girdle muscular dystrophy; BMD – Becker’s muscular dystrophy; DM – Myotonic Dystrophy 
(Dystrophia Myotonica); ZCM – zero crossing mode; PIM – proportional integration mode; SAM – step activity monitor; REE – resting energy 
expenditure; TEE – total energy expenditure; PAL – physical activity level (index=TEE/REE); ACTEE – Active energy expenditure (TEE minus REE); 
RPE – rating of perceived exertion; HR – heartrate; bpm – beats per minute; VO2 max – maximal oxidative capacity; METs – Metabolic equivalents; 
CBT – cognitive behavioural therapy; AET – aerobic exercise training; 6MWD – 6-minute walk distance; ANOVA – Analysis of Variance; ANCOVA 
– Analysis or covariance; N/R – not reported.
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